|
|
·|û¡GS.H10000301 µoªí®É¶¡:2013/4/22 ¤U¤È 10:23:12
|
À°¦£""·|û¡G²q·Q10136148""¶KӤ峹¡A¦]¬°¥L¥»¤H¤£ª¾¹D¸Ó«ç»ò¶K¨ì¿³Âdª©¨Ó~~~ ³o¬O¤@½g§¹¥þ©M¯E¹©µLÃöªº¤å³¹ ¦ý¦n¹³¤S¦³©ÒÃöÁp ¦]¬°¯E¹©¤]¦P¼Ë¦bµo®i³o®M§Þ³N ¦b³oÓ²{ª÷¼W¸êªºªÑ»ù½pÀq´Á(²qªº) ¤]³\¤j®a¨Ó°Ê°Ê¸£ ¸Ñ¸ÑªÑ»ùªº´e ´N¦p¦P¼ÐÃD ±z·Q¨ì¤°»ò©O? ½Ð¤j®a¦h¦h±·³õ ÁÂÁ±z! ¥Íª«¼Ð°O(Biomarker)¬O§ÜÀù¥P¤¦(Anticancer Drug)¡H ª¾Ãѳq°Tµû½×²Ä60´Á ³z¹L°ò¦]ÀË´úµo²{Àù¯g¬O¥i¦æªº¡C¦ý¬O±¹ï¦h¦p¤û¤òªº¦UºØ¥Íª«¼Ð°O¡A¤â¤W¨S¦³¨¬°÷¬ã¨s¸g¶Oªº¬ã¨s¤Hû¡An§â¥Íª«¼Ð°O¤ÀªR§Þ³N±a¶i¥«³õ¦¨¬°¯e¯f¶EÂ_ªº¤@Àô¡A¹ê¦b§xÃø¡C °ò¦]ÅéÂå¾Ç¤£Â_¶i¨B¡A¤Î®Éµo²{¨Ã¥Bºë½T´x±±Àù¯gªº¦´Á¼x¥ü¤£¦A»»¤£¥i¤Î¡C¬ã¨s¡u¤À¤l¥Íª«¼Ð°O¡v(molecular biomarker)¡A¥i¥HÀ°§U§Ú̵o²{¯e¯fªºªì´Á¯gÔ¡A¤]¥i§Y®É¶i¦æ¦³®ÄªºªvÀø¡CµM¦Ó¡A³oÓ¹Ú·Q¦Ü¤µ¤´¥¼¹ê²{¡C ¥þ¥@¬Éªº¹êÅç«Ç³£¦b¿n·¥´M§ä¥i¥Î¨Ó°»´ú¯e¯fªº¥Íª«¼Ð°O¡C¦ý¬On§â³oºØ¥Íª«¼Ð°Oª¾Ãѵo®i¨ì¯à°÷¥Î©ó¯e¯f¶EÂ_¡AÁÙ¦³¤@¬qªø¸ôn¨«¡C¬ü°ê¬F©²ªº¥DºÞ¾÷Ãö¥Ø«eÁÙ¨S¦³§åã¥ô¦ó¤@¶µ¥Î©ó¦´Á°»´ú¯e¯fªº¶EÂ_¸ÕÅçªk¡C ©¬´µÂå®v¡]Harvey Pass¡^»¡¡A¥Íª«¼Ð°O³Ì«nªº¥\¯à¡AÀ³¸Ón¯à«ü©úÀ³·í±Ä¦æªºªvÀø¤èªk©Î¯e¯fªº¯f²zª¬ªp¡C ÂåÃIJ£·~Æ[¹î®a»¡¡An½T©w¬YºØ¥Íª«¼Ð°O¬O§_¥i¥HÀ°§U§ÚÌ°»´ú¯e¯f¡A¤Q¤À§xÃø¡A¨S¦³¤H¯à«OÃÒ³o¨Ç¥Íª«¼Ð°O·|Åܦ¨¯à°÷¦æ¾P¤W¥«ªº¯e¯fÀË´ú§Þ³N¡C¦¹¥~¡AÁÙ¦b¹êÅ綥¬qªº¥Íª«¼Ð°OºØÃþÁc¦h¡An¿ï¥X¤@ӳ̦³µo®i¼ç¤Oªº¼Ð°O¡A¤]¤£®e©ö¡C Âå®v³£§Æ±æ³oºØ¥Íª«¼Ð°OÀË´ú¯à°÷À°§U¥Ļä¨ì¹ï¯S©w¯f±w¦³®ÄªºÀøµ{¡C°ÝÃD¦b©ó¡A·í³o¨Ç¥Íª«¼Ð°O¥u¯à¥Î©ó¯f±¡¶EÂ_«oµLªk©ú½T«ü¥XªvÀø¤èªk®É¡AÂå®v¬O§_Ä@·N±Ä¥Î¡C ¬ü°ê¯Ã¬ù¤j¾ÇÂå¾Ç¤¤¤ß±Mªù¬ã¨s¶¡¥ÖÀù¡]mesothelioma¡A¯Ý¸¡µÄ¤ºÅ¨²Õ´ªº´c©Ê¸~½F¡^¥Íª«¼Ð°OªºÂå®v©¬´µ¡]Harvey Pass¡^»¡¡A¥Íª«¼Ð°O³Ì«nªº¥\¯à¡AÀ³¸Ón¯à«ü©úÀ³·í±Ä¦æªºªvÀø¤èªk©Î¯e¯fªº¯f²zª¬ªp¡C ¤C¦~«e¡A¬ü°ê°ê®aÀù¯g¬ã¨s©Ò¦¨¥ß¤F¡u¦´Á°»´ú¬ã¨sºô¡v¡]EDRN¡^¡A§Æ±æÂǦ¹½T»{¥Íª«¼Ð°O§Þ³Nªº¥i¾a«×¡A«Ø¥ß¤@®MÀË´ú»PÅçÃҥͪ«¼Ð°O¬O§_¦³®Äªº¬yµ{¬[ºc¡C³oÓ¤uµ{¬Û·í¯E¤j¡A¦]¬°¯e¯f¶EÂ_ÀË´ú³q±`»Ýn¦P®É¹B¥Î¦n´XºØ¤£¦Pªº¥Íª«¼Ð°O¡A¤~¯à½T«OÀË´úµ²ªG¦b²Îp¤W¬O¦³ÅãµÛ·N¸q¡C ´ú¸Õ¶i¦æ¤¤ EDRN³oÓºô¸ô´£¥X¤@Ó¦p¦óµû§P¥Íª«¼Ð°O¬O§_¦³®Äªº¯ó®×¡A¤]«ü¥X¤F¦UºØ¦³Ãö¼h±¡CEDRN¦b¦¨¤d¤W¸UºØ¼ç¦b¥Íª«¼Ð°O¤¤¿ï¥X¤F¤@¦Ê¤ÜºØ¡A³o¨Ç¥Íª«¼Ð°O¤]¦U¦b¤£¦Pªº¬ãµo¶¥¬q¡C ³o¤@¦Ê¤ÜºØ¥Íª«¼Ð°O¡A¬O¶¡¥ÖÀù¡B¨xÀù¡B»H¯ÖÀù¡BÄáÅ@¸¢Àù»PªÍÀù³o¤ºØÀù¯gªº¥Íª«¼Ð°O¡A¦³ªº¤´¦b¬ãµoªº²Ä¤T¶¥¬q¡A¦³ªº¤w¸g¶i¤J³Ì«á¶¥¬q¡A¨Ã¥B³z¹L¤j³W¼Òªº¤HÅé¸ÕÅçÁA¸Ñ¨ä°»´ú¯e¯fªº®ÄªG¦p¦ó¡C ¬ü°ê°¨¨½Äõ¦{¥Íª«¬ì§Þ¤½¥qCangen Biotechnologies¤]°Ñ»P¤FEDRNpµe¡A¥ĻӦb¦¨¬°²Ä¤@Ó§âDNA¬°°ò¦ªº»H¯ÖÀù¦´Á°»´ú§Þ³N±À¤W¥«³õªº¤½¥q¡C¸Ó¤½¥qªí¥Ü¡A¥L̹ï¦Û¤v¬ãµo¡B¥H¤Q¤ÓDNA¤ù¬q²Õ¦¨ªºÀËÅç¤u¨ã«Ü¦³«H¤ß¡A³oºØÀËÅç¤u¨ã¥i¥H¤ñ¨ä¥L¶EÂ_¤è¦¡§ó¦µo²{¸~½F¡C ¤£¹L¡AÁöµMÂå®v¥i¥H¥Î³oºØ¤u¨ã§ó¦µo²{¸~½F¡A¤j³¡¤Àªº»H¯ÖÀù±wªÌÁÙ¬O±o¸g¾ú¤â³N¡C´«¨¥¤§¡A³oºØ·sªºÀËÅç¤u¨ã¹ï©ó»H¯ÖÀù¯f±wªº¦s¬¡²v¥u¦³»´·L¼vÅT¡C Cangen¤½¥q¬ã¨s³¡ªù¥DºÞ¦ãºqªi¡]Eddy Agbo¡^»¡¡A³z¹L¥Íª«¼Ð°O§ä¥X¥i¥HªvÀøªì´Á¸~½Fªº·sÃĪ«Àøªk¡A¬O¥LÌ¥¼¨Óªº¬D¾Ô¡CµM¦Ó¡A¥Ñ©ó³oºØ·s¦¡ÃĪ«ÀøªkÁÙ¨S°Ý¥@¡A¬ü°êªºÂå®v»P¤ä¥IÂåÀø·ÓÅ@¾÷ºc¶O¥Îªº«OÀI¤½¥q¡A¹ï¥Íª«¼Ð°Oªº¿³½ì·|«Ü¦³¡C »sÃIJ£·~¸ê·½Â×´I¡A¤]³\¯à¨Ï¥DºÞ¾÷Ãö§åã¥Íª«¼Ð°OÀË´ú§Þ³N¡C¤£¹L¡AÃļt¤ñ¸ûÃö¤ßªº¡A¬O¦p¦ó³z¹L¥Íª«¼Ð°OÁA¸Ñ±wªÌ¾A¤£¾A¦X¨Ï¥Î¬YºØÃĪ«¡AÃļt¹ï¦´Á°»´ú¿³½ì¯Ê¯Ê¡C ¥[¦{Genentech¤½¥q¬ãµo¥X§Ü¨ÅÀùÃĪ«Herceptin¡A¬OÓ¦¨¥\®×¨Ò¡CHerceptin¦®¦bªvÀø¨º¨ÇÅ餺¹L«×ªí²{¬YºØ¨üÅ骺¨ÅÀù±wªÌ¡C¥ú¬O¥h¦~¡AHerceptin´N½æ¤F¤Q¤T»õ¬ü¤¸¡C microRNAs ¦è¶®¹ÏºÖ·ç¼w»®ª÷´ËÀù¯g¬ã¨s¤¤¤ß¤À¤l¥Íª«¾Ç®a«¢«n³\¡]Sam Hanash¡^»¡¡A¤j®a³£§Æ±æ¬Ý¨ì¥Íª«¼Ð°O§Þ³N¥X²{À¸¼@©Êªº¦¨¥\¡C«¢«n³\»¡¡A²~ÀV¤£¦b©ó¹êÅç«Ç¸Ìªº¬ì¾Ç¬O§_¥ý¶i¡A¦Ó¬O¬ã¨s¤Hûn¦p¦ó¦b¨º»ò¦hºØ°ò¦]¡B³J¥Õ½è»P·LRNA¡]microRNAs¡^¤¤¥h¿¾¦sµ×¡A§ä¥XÁ{§É¤W¦³¹ê¥Î»ùȪº¥Íª«¼Ð°O¡C¥L»{¬°¡A¥Ø«eªºª¬ªp´N¹³¬O¬ü°ê¦è³¡©Ý¯î®É¥N¡A¨CÓ¤H³£¯à«Å¥Ü¾Ö¦³¤@¤ù¤g¦a¡A¨CӾǪ̤]³£¯à«ÅºÙµo²{¬YºØ¥Íª«¼Ð°O¡C ¥ß¤U¼Ð¬ñ EDRN¶O¤F¤@µf¥\¤Ò´M§ä³Ì¦³¼ç¤Oªº¥Íª«¼Ð°O¡A¦nÅý³o¨Ç¥Íª«¼Ð°O¶i¤JÁ{§É¸ÕÅ綥¬q¡CEDRN¤w¯à´£¨Ñ¥Î©ó¬ã¨sªÍÀù¡B¨ÅÀù¡B§Z±_Àù¡BÄáÅ@¸¢Àù©Mµ²¸zÀùµ¥Àù¯g¥Íª«¼Ð°OªºÀù¤Æ²ÓM²Õ´¡B¦å²M»P¦å²G¼Ë¥»¡C¬ì¾Ç®a¥i¥H¥Î³o¨Ç§÷®Æªì¨BÀËÅç¥Íª«¼Ð°Oªº¥i¾aµ{«×¡C EDRN¤]«Ø¥ß¤FÅçÃҥͪ«¼Ð°O´ú¸Õ®ÄªGªº«~ºÞ¼Ð·Ç¡A¦³¤@¾ã®M§e²{¸ê®Æªº¼Ð·Ç¨t²Î¡CEDRNÁÙ»P¬ü°ê°ê®aÀù¯g¬ã¨s©Òªº¨ä¥L¹Î¶¤µÛ¤â«Ø¥ß¤@Ó¤j³W¼Òªº¤HÅé¥Íª«¼Ë¥»Àx¦s®w¡]human biosample collection¡^¡C ±M®a»{¬°¡A³o¨Ç¨BÆJ½T¹ê¦³¨ä¥²n¡A¦ý¬O³o¨Ç§@ªk¤£¤@©w¯à§â¥Íª«¼Ð°O´ú¸Õ±a¨ì¥«³õ¤W¡C¦b³Â¦{¥¬¬¥¼w¬ã¨s©Ò¡]Broad Institute¡^¬ã¨s³J¥Õ½èÅ骺¦N¥ß¯S¡]Mi |
|
·|û¡G¨ÏªÌ10136366 µoªí®É¶¡:2013/5/12 ¤U¤È 11:29:28²Ä 117 ½g¦^À³
|
¤@¯ë»¡¨Ó,¥xÆWÃļtÃÄ«~»ù«O»ù¬°¬ü°ê¤W¥«»ù®æªº50%, ²{dificid ªº»ù®æ¥u1/3, ¬ü°êoptimerYn¦Ò¶q¥þ²y¥«³õ, ¥xÆW»ù®æªÖ©w·|¼vÅT¨ä¥L°ê®a, ¦AªÌ¡A²{¤µÂå°|¤@¯ëªº¶iÃĦ¨¥»¤j³£爲»ù«O»ùªº70-80%, ¨º1404¤¸¸gÂå°|§é¦©«á¡A¬O§_·|§C©ó¶iÃĦ¨¥»¡H ¦p¦¹, Dificid ¬O§_¯à¶¶§Q¨Ì¦¹°·«O»ù¶¶§Q¤W¥«¡AÀ³ÁÙ¬O¥¼ª¾¤§¼Æ? |
|
|
·|û¡G´µ¯S10135783 µoªí®É¶¡:2013/5/12 ¤U¤È 08:33:45²Ä 116 ½g¦^À³
|
Dificid °·«O»ù¨C²É1404¤¸,ºâ¤£¿ù ¦ý¨î©ó²Ä3½u¥ÎÃÄ,¥Î¶q¥²¤£¦h ¹w¦ôÀ禬¤£·|¶W¹L1000¸U/¤ë ¹ï©ó¯E¹©¨Ó»¡«Å¥Ü·sÃĤW¥«ªº·N¸q¤j©ó¹ê½è·N¸q |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/5/12 ¤W¤È 10:11:06²Ä 115 ½g¦^À³
|
·PÁ´µ¯S¤jµL¨pªº¤À¨É©M±M·~ªºµû½× Åý§Ú̦b°g¯í¤¤¦^¯«¤F ±z¨¥Â²·N¸ðªº»¡©ú ´X¥G§âOBI-822©Î833 ¥¼¨Ó¥i¯àµo®iªº¤è¦V ¥þ±Ån¬A Herceptin·|½æ±o¶W¥G·Q¹³ªº¦n ´N¬O¦b¤W¥««á Ä~Äò¶}µo»P¥LºØÃĪ«ªº·f°t ¨Ó©µ½w´_µo OBI-822©Î³\¤]´Â¦¹¤è¦Vµo®i ¦b¦ ¤¤´Á±wªÌ ¥Î¤â³N ©ñÀøªvÀø«á ¦A¥ÎOBI-822¨Ó©µ½w´_µo ²¾Âà ¤p§Ì²q·Q OBI-822ªºÁ{§É¸ÕÅç¥HPFS¬°¥Dnµû¦ô¥Ø¼Ð °£¤FÁYµuÆ[¹î´Á(¤£YOS»Ý®É¬Æ¤[)¥~ ¥i¯à¤]Áô§t´Â¦¹¤è¦Vµo®iªº·N«ä Y¯à¦¨¥\ ©Î±N¶W¶VHerceptin¥Ø«eªº¾P°âªí²{(³o¥u¬O¤p§Ì¼ÖÆ[ªº²q´ú) ¤p§Ì«D±`¨ØªA´µ¯S¤j±zªº±M·~»P²´¥ú ¥¼¨Ó¤´½Ð±zÄ~Äò±a»â§Ú̦¨ªø «D±`·PÁ±z! ¤]·PÁª̤j¤j À°§ÚÌ»`¶°DIFICIDªº¸ê®Æ Åý§Ú̧ó¥[¤F¸Ñ¥¦ ÁÂÁ±z! ¥t¦³¤j¤j½Í¤Î²{¼Wªº¸ÜÃD ¤½¥q²{¼W©|¥¼°e¥ó ©Î³\¤£¬O¦æ¬F®Ä²v°ÝÃD ¤p§Ì²q·Q ¥H¤½¥q·ÓÅUªÑªFªºÆ[ÂI ¤½¥qÀ³¦³¨äªº¦Ò¶q ©Î³\¤½¥q¦bµ¥¥x·LÅé5/20ªº²{¼W¥Í®Ä¤é ¨ÓÆ[¹î¥DºÞ¾÷ÃöªººA«× ¥H§K³Q°h¥ó ³y¦¨ªÑ»ù¿E¯P¾_Àú ·l¤Îéw ¥t¤@Ó¥i¯à¬O¤½¥q¦bµ¥«Ý¤@Ӯɶ¡ÂI ---¬Y¨Ç¨Æ±¡ªºµo»ÃÂI ¨ä¤@ ¤p§Ì·Q¬ODIFICID ¨ä¤G¬O¤p§Ì¥ý«e´£¹Lªº¬Y¨Æ¥ó ¤£¹L³o¨Æ¾Þ¤§¦b¥L¤H ¤½¥q¥i¯à¤ñ¸û¨S§â´¤ ¤p§Ì²`ı¯E¹©¤½¥qªº°ª¼h¤£Â²³æ ¤£¥u¬O±M·~¯à¤O ¦æ¨Æ¤W¥ç³B³Bªí²{¥X ¹ï¤H¹ïªÑªFªºÅé¶K©MÃöÃh §ë¸ê³o¼Ëªº¤½¥q ±z¤£Ä±±o©¯ºÖ¶Ü? ÁÂÁ¤j®a! |
|
|
·|û¡GIriswu10136250 µoªí®É¶¡:2013/5/12 ¤W¤È 09:36:30²Ä 114 ½g¦^À³
|
¨ä¹ê¥Î¬ü°êªº«O¶O¸ò¥xÆW¤ñ,®t¤T¿ºâ¬O«Ü¦X²zªº.ÀH«K¶iÓ¥[Å@¯f©Ð¥i¯à´N¶W¹L10¸U¬üª÷¤F. |
|
|
·|û¡Gbill10135881 µoªí®É¶¡:2013/5/12 ¤W¤È 09:23:56²Ä 113 ½g¦^À³
|
¤@Áû¦³Àø®Ä¯à®¾¦^¥Í©RªºÃÄ 1400¤¸¨Ã¤£¶Q ¦pªG¤@Áû¤£¯àªv¤H©RªºÃÄ ´Nºâ½æ10¤¸¤]ºâ¶Q ¬Û¦P¤@ÁûÃÄ ¬ü°ê¯à®Öã½æ4200 ¥xÆW®Öã½æ1400 ¦n¹³¥xÆW¤H©R¤ñ¸û¤£È¿ú? |
|
|
·|û¡G¨ÏªÌ10136366 µoªí®É¶¡:2013/5/11 ¤U¤È 09:23:29²Ä 112 ½g¦^À³
|
¸g¬d¸ß°·«O¥ÎÃÄ»ù®æ, pºâ10¤ÑÀøµ{Á`¶O¥Î¡A µo²{²Ä¤@½u¥ÎÃÄÀøµ{Á`¶O¥Î¤£¶W¹L150¤¸¡A ²Ä¤G½u¥ÎÃÄÀøµ{Á`¶O¥Î¤£¶W¹L1500¤¸¡A ¨Ìdificid ²{°·«O»ù¨C²É1404¤¸¡A1¤Ñ2²É¡AÀøµ{Á`¶O¥Î±N°ª¹F28080¤¸¡C |
|
|
·|û¡G¨ÏªÌ10136366 µoªí®É¶¡:2013/5/11 ¤U¤È 09:05:04²Ä 111 ½g¦^À³
|
¥Ñ°·«O§½¤½¶}ªº4¤ë·|ij°O¿ý¤¤¤]«ü©ú¡A ¦]dificid »ù®æ°ª©ù¡A¦Ò¼{©w¨Ï¥Î½d³ò¡A ¦p¦b²Ä¤@½umetronidazole ¤Î²Ä¤G½uvancomycinªvÀø¥¢±Ñ©ÎªvÀø´_µo«á¤~¯à¨Ï¥Î¡A ¦ý¤´·|»P·P¬V¬ì¡A¸zG¬ì¡A¸~½F¬ìµ¥±M§QÂå®v°µ°Q½×¡C ·PıY¦¨¬°²Ä3½u¥ÎÃĤÎÃÄ«~»ù®æµ¥¦]¯À¡A¥¼¨Ó·|¨Ï¥Î¯f¤Hªº¤H¼Æ¦³¦h¤Ö¡H |
|
|
·|û¡G¨ÏªÌ10136366 µoªí®É¶¡:2013/5/11 ¤U¤È 08:39:19²Ä 110 ½g¦^À³
|
Dificid ®Ú¾Ú¬ü°êºô¯¸¤½¥¬¡A¥¦¬O¦b2011¦~¤W¥«¡A ¨äÀøµ{10¤Ñ¡A¨C¤Ñ2²É¡AÁ`Àøµ{¶O¥Î¬°2800¶ô¬üª÷¡A §Yªí¥Ü¦b¬ü°êªº¨C²É°â»ù¬°140¶ô¬üª÷(¬Û·í¥x¹ô4200¤¸)¡C |
|
|
·|û¡GIriswu10136250 µoªí®É¶¡:2013/5/11 ¤U¤È 07:48:35²Ä 109 ½g¦^À³
|
«õ,³o¬O¤°»òÃĪü.¤@Áû³ºµMn1400¦h¤¸.³oÓÃÄ»ù¤w¸g§â§Úµ¹À~·w¤F.¥u¬O¤@ºØ§Ü¥Í¯À³ºµM³o»ò¶Q¼Ú. |
|
|
·|û¡G¨ÏªÌ10136366 µoªí®É¶¡:2013/5/11 ¤U¤È 07:36:48²Ä 108 ½g¦^À³
|
·PÁÂ"´µ¯S¤j¤j¡¨´£¨Ñºô§}¡A ¸g¬d¸ßµo²{¦b°·«O§½4¤ë·|ij°O¿ý¤¤¤wµ¹¥Idificid»ù«O»ù¡A ¨C²É1404¤¸(³Q©eû»{©wÂkÄÝ2A¯Å¡A«D1 A¯Å¬ð¯}³Ð·s·sÃÄ¡^ ¦¹»{©wÀ³¥i¯à»·§C¤½¥q©Ò¹w´Á(¥]¬A»ù®æ¤Î·sÃįżƻ{©w¡^¡A À³·|Ä~Äò¥ÓÂФU¥h¡A¦ý©È¥¼¨Ó®³¨ì´Á±æ»ù®æ¤Î·sÃÄ°ª¯Å¼Æªº¾÷·|·|±Á{ªÅ«e¬D¾Ô¡C |
|
|
·|û¡GIriswu10136250 µoªí®É¶¡:2013/5/11 ¤U¤È 06:31:19²Ä 107 ½g¦^À³
|
¤£À´¬°¦ó¤½¥q¤@Ó¤ë«e´N«Å¥¬n²{ª÷¼W¸ê,¦ý¬O¨ì²{¦b«o³£ÁÙ¨S¦³°e¥ó.Ãø¹D¦³¤°»òÅܤƶÜ? |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2013/5/11 ¤W¤È 11:56:06²Ä 106 ½g¦^À³
|
«¢«¢«¢!¥´¤Ó§Ö³ºÃn¥ú!(¤]³\¬O¬G·Nªº) §Úªº±b¸¹¥Ã»·®ø¥¢¤F! ¦U¦ì¦A¨£! |
|
|
·|û¡G¤ý·©¿³10134649 µoªí®É¶¡:2013/5/11 ¤W¤È 11:47:53²Ä 105 ½g¦^À³
|
¨º´N¤Ó¦n¤F! ¤U§«ô¤@©tª`¤@ÂY,¥þÀ£! |
|
|
·|û¡G´µ¯S10135783 µoªí®É¶¡:2013/5/11 ¤W¤È 11:46:25²Ä 104 ½g¦^À³
|
Phase III¬OÂùª¼,ªí¥ÜÂå¥Í¤Î¯f¤H¬Ò¤£ª¾¬O¨º¤@²Õ ¹êÅç²Õ: OPT-822/OPT-821¥[¤Wcyclophosphamide ¹ï·Ó²Õ: placebo¦w¼¢¾¯¥[¤Wcyclophosphamide µû¦ô«ü¼Ð(endpoint) 1. ¥Dnµû¦ô«ü¼Ð¡G ƒÜ µL¯e¯f¶i®i¦s¬¡´Á (progression free survival, PFS) 2. ¦¸nµû¦ô«ü¼Ð¡G ƒÜ Á`¦s¬¡´Á (overall survival, OS)- ©Ò¦³¨ü¸ÕªÌ±N·|³Q°lÂܤ¦~ ƒÜ Åé²G©Ê§K¬Ì¤ÏÀ³(µû¦ôGlobo H ªºIgG¥H¤ÎIgM§K¬Ì¤ÏÀ³)¡C ƒÜ ¦w¥þµû¦ô- ¤£¨}¤ÏÀ³¡A¨Ö¥ÎÃÄ¡A¹êÅç«ÇÀˬd¡A¥Í©R¼x¶H¥H¤Î¤ß¹q¹Ï Phase III±q2012,11¶}©l¦Ü¥Ø«e³sµL¯e¯f¶i®i¦s¬¡´Á (progression free survival, PFS)³£¤£¥i¯à¦³¼Æ¾Ú§ó¤£¥Î»¡Á`¦s¬¡´Á (overall survival, OS)- ©Ò¦³¨ü¸ÕªÌ±N·|³Q°lÂܤ¦~,³Ì§Ö¤]n2013¦~©³¤~¥i¯à¦³³¡¥÷ PFS¼Æ¾Ú,§Y¨Ï¦³¤]¥u¦³p¹ºÁ` ¥D«ù¤H ¥x¤j¶ÀÂå®v¤Î¤½¥qª¾¹D,¦ý¬O¥L̳£Ã±«O¯µ¨ó©w,¤]¤£¯àÁ¿,¨ä¹ê±q¤½¥qªº°Ê§@´Nª¾¹D¦n¤£¦n,¦pªG¤£¦n»°§Ö±ÂÅv°ê»ÚÃļt³]¤U°±·lÂI¥H´î¤Ö·l¥¢,¦ó¥²¦Aªá¿ú¥h°µ®ü¥~PHASE III, ¥Ø«e§A¦³¬Ý¨ì¥xÆW¥Í§Þ¤½¥q´±¦Û¤v°µ®ü¥~PHASE III¶Ü? |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/5/11 ¤W¤È 11:43:16²Ä 103 ½g¦^À³
|
£~£~¤j ¹ï¤£°_ ¤p§Ì´¡¨Ç¸Ü ¨Ì¤p§Ì¬Ý ±z¤]¤£¥Î¦A¬°Ãø´µ¯S¤j¤j¤F ¤W½g¥L¤w§âµ²½×Á¿±o«Ü²M·¡¤F ³o½g¤]¦h©Ò·t¥Ü ±z¤£Ä±±o´µ¯S¤j¤jªº¥Î»y¸ò§Ṳ́£¤@¼Ë¶Ü ¤p§Ì¤£¯à¦A¦h»¡¤F ½Ð´µ¯S¤j¤jÄ~Äò±a»â§ÚÌ«e¶i ·PÁ±z! ¤p§Ì«e¨¥·Q±qÂå¾ÇÛ²z©M¯f±wÅv¯qªº¨¤«×¨Óµo¨¥ ¦ý¬Ý¨ì´µ¯S¤jªº»¡©ú ¤p§Ìı±oµL¶·¦h¦¹¤@Á| ¤j®a¸òµÛ´µ¯S¤j´N¹ï¤F |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2013/5/11 ¤W¤È 11:01:51²Ä 102 ½g¦^À³
|
´µ¯S¤j¤j,±z¬O§_¯à§Ë¨ì¤@¨Ç¥Ø«eOBI822 Phase III ªº³Ì·s±¡ªp©Î¼Æ¾Ú? ©ÎªÌ¯à§_°Ý¨ì¤@¨Ç°Ñ¥[¸ÕÅ窺Âå®v©Î¯f¤HªºÁ¿ªk? |
|
|
·|û¡G´µ¯S10135783 µoªí®É¶¡:2013/5/11 ¤W¤È 10:01:33²Ä 101 ½g¦^À³
|
Àù¯g²Ä¥|´Á¬O«ü¦³»·³B¾¹©xÂX´²Âಾ,5¦~¦s¬¡²v¤@¯ë¤p©ó10% ´X¥G¤j³¡¥÷§ÜÀùÃĪ«,³£±q²Ä¥|´Á¶}©l°µÁ{§É¸ÕÅç,µ¥¤W¥«¤§«á¦A©¹«e±À¦Ü3´Á2´Áªº¯f¤H,Àù¯g¥|´Áªº¯f¤H°Ñ¥[Á{§É¸ÕÅ窺·NÄ@¸û°ª,¥²³º§ÜÀùÃĪ«¤]¬O¦³°Æ§@¥Î,¤×¨ä¬r±þ«¬ÃĪ«,¦p¨S¥Í©R«Â¯Ù,¨S¦³¤HÄ@·N·í¥Õ¦Ñ¹«¥h«_·ÀI.¦]¦¹ÃĪ«ªº°Æ§@¥Î·|¼vÅT¦¬®×¶i«× ¨S¿ù¯f¤Hªº§K¬Ì¤O¤@©w·|¼vÅT²£¥Í§ÜÅ骺¯à¤O,·íµM¥Î¦b¨S¥´¹L¤ÆÀø©Î3´Á2´Áªº¯f¤H¤@©w·|§ó¦n.©Ò¥HOBI822 Phase III ¿ïªº¯f¤H¬OÅé¤O¸û¦nªº¯f¤H(perfomance state 0 ¤Î I ) Åý¼Æ¾Ú§ó¦n,¥H¼W¥[¦¨¥\¾÷·|, µ¥¤W¥«¤§«á¦A©¹«e±À¦Ü3´Á2´Áªº¯f¤H,¬Æ¦Ü¹w¨¾¨ÅÀù,¦]¬°IgG§ÜÅé¨ã¦³°O¾Ð©Ê |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/5/11 ¤W¤È 09:03:04²Ä 100 ½g¦^À³
|
©ú¤Ñ¬O¥À¿Ë¸` ¯¬ºÖ¶ý¶ýÌ ¥À¿Ë¸`§Ö¼Ö ©¯ºÖ¥Ã»· ÁÂÁ¤j®a! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/5/11 ¤W¤È 08:52:06²Ä 99 ½g¦^À³
|
ªê¤j§ë¸êªÑ²¼ ¯u¬Oªêªê¥Í· ¤H¦p¨ä¦W°Ú ¥O¤H¦n¥Í¸r¼}! ºÙ±z¡¨§ë¸ê¨å½d¡¨¤@ÂI¤]¤£¬°¹L «D±`ȱo§ÚÌ¾Ç²ß ¤£¹Ln²ß±o¦p±zªº@¤ß¼Ý¤O ¨Ã«D©ö¨Æ ¤ßºA½Õ¾ã©M«ùªÑ«H¤ß ©Î¬°ÃöÁä ¿ï¹ïªÑ²¼ ®É¶¡´NÅܦ¨°]´Iªº¦nªB¤Í °]´I´N¦b½Í¯º¶¡²Ö¿n ©Ò¥H¤´½Ðªê¤j¤£§[Ä~Äò¤À¨É±z§ë¸ê¤ß±o ¥¿©Ò¿×¡¨ ¬J¥H¬°¤H¤v·U¦³¡A¬J¥H»P¤H¤v·U¦h ¡§ ¦h¦æµ½¨Æ ¦h¤À¨É§O¤H ¦ÛµM¦a¦Û¤v¤]·|·U¨Ó·U´I¦³§r! «D±`·PÁ±z! ¬ðµMı±o¡¨ªê¤j¡¨³oÓ¦W¦r¦n¦Õ¼ô ¦³µÛ¶m«äªº¿Ë¤Á ªÌ¤j¤j ±z¹ê¦b¦³°÷¼ö¤ß ¤SÁæ¦Ó¤£±Ë°lµÛ¤p§Ì ¤p§Ìı±o¨Ì±zªºÓ©Ê©M¦Û¨úªº¦W¦r"¨ÏªÌ" ¶}Ó¬õ®Q¤½¥qÀ³·|«Ü¦¨¥\ ·|«ÜÁÈ ±z¹ïOBI-822¤W¥«®Éµ{ªº¦ôºâ ¤p§Ì¤í¯Ê±M·~¯à¤O ¦A¤]µL¤O»P±zÅG»é ±z´N°ª©ï¶Q¤â ÄǤF¤p§Ì§a ÁÂÁ±zªº«ü±Ð ¤p§Ì»{¿é¤F ¥un¤j®a³£¥i¥H«Ü§Ö¼Ö¦a¤jÁÈ ¤p§Ì´N¤ß¤w¨¬¨o ÁÂÁ±z! ´µ¯S¤j¬OÓ°ª¤â ¤p§Ì©ß¿j¤Þ¥Éªº¥ô°È¤w¹F ¤p§Ì¥u¬O¤@Ó·R»¡¸Üªº©@ ¨Æ¹ê¤W¤p§Ì¤w¬OÀrÆj§Þ½a¤F ¤p§Ì¤]·Q©M¤j®a¸òµÛ´µ¯S¤jªº¸}¨B¾Ç²ß ¦ý¤p§ÌY¤S¦³¨ä¥L·sªº²q·Q ¤´·|©M¤j®a¤À¨É ¤p§Ì²`«H¦b§Ṳ́§¶¡ªº¤j¤j ¤´¦³³\¦h¨Âä£ÅSªº°ª¤â ª¾ÃѯEÃv ¸ê®Æ®ü¶q ¹ê«D¤@¤H¤@¤v¤§¤O ©Ò¯à³Ó¥ô °ß¦³¤j®aÄ@·N¤À¨É §Ú̯E¹©®a±Úªºª¾ÃѤ~¯à§§¤j µL½×±z¬OÁ¿¦hÁ¿ªÅ ¥un±z¦³¥ß½×°ò¦ §Ú·Q¤j®aÀ³¦h·|Åwªïªº ¦h¤F¸Ñ§ë¸ê®Éµ{¤¤ªº¦hªÅ¦]¯À ©Î¦³§U©ó§Ú̪º§PÂ_©M¦]À³ O¤jªº°ÝÃD ¯u¬O¤j«v°Ý «D¼ç¤ß±M¬ã¦b³oÓ»â°ìªº±M·~¤Hû ®£©ÈÃø¥H¦^µªªº«Ü§¹µ½ Àù²ÓM¹BÂà¾÷¨î¬O«D±`½ÆÂøªº ¤HÃþ¦Ü¤µªº¬ã¨s¦¨ªG ¥i¯à¤]¥u¬O½M¤lºN¶H ¬ì¾Ç®a¸Õ¹Ï¦b²³¦h«ÜªK¸`¤Æªº¬ã¨s¤¤ ¥h«÷´ê¦¨¤@°¦¶H ¦b³o°¦½ü¹ø¨Ì«ܼҽkªº¶H¤¤ ¥Î¤À¤l¥Íª«¾Ç ¥Íª«¤Æ¾Ç¥h´M§ä¤@ºØ¤è¦¡©Î¤À¤l §â¯e¯f¥Í¤Æ¤ÏÀ³¹Lµ{ªº¬YÓÂI¤ÁÂ_ ³oÓÂI¥i¯à¦³¦¨¤d¤W¸UÓ ¦³¤H§ä¨ìªº ¬O¤jÂ_ÂI ¤S¯à§ä¥X¤@ºØ¤À¤l§¹¬ü¤ÁÂ_ ©Ò¥HÃĮĦn ¦³¤H¥i¯à§ä¨ì¤pÂ_ÂI Àù²ÓM¥i¯à«Ü§Ö´N§ä¨ì¦]À³ ¦Ó²£¥Í§ÜÃÄ©Ê ¤p§Ì¥u¬O¦b©Ò¾\Ūªº¸ê®Æ¤¤ ¦³¦p¦¹ªºÅé·| ¦Ü©ó¥¿¤£¥¿½T ¤p§Ì¤]²ö®_¦Ï ¤´±o½Ð±M®a«ü¾É O¤j°Ýªº¬O´µ¯S¤j ¤p§Ì¬O¦³¨Ç¬Ýªk ¦ý°ò©ó´L««e½ú ¤p§Ì¤£´±³y¦¸´¡¶¤ ¾÷Â઺²z½× ¤p§Ìµ´¹ï¬O¤£À´ ¦ý¤p§Ì·|±qÂå¾ÇÛ²z©M¯f±wÅv¯qªº¨¤«× ¨Ó¬Ý«Ý³oÓ°ÝÃD ±q¹L¥h¤p§Ìªº¾ú¦¸¦^À³¤¤ ©Î³\¦³¤j¤j¤w¸g¥i¥H²q¥X¤p§ÌnÁ¿¤°»ò¤F «¢! ¦]¬°¤p§Ìª¾¹Dªº ´N¥u¦³¨º¨Ç ®ö¶O±zªº®É¶¡ ÁÂÁ¤j®a! |
|
|
·|û¡Gªüªê10136308 µoªí®É¶¡:2013/5/10 ¤U¤È 04:21:21²Ä 98 ½g¦^À³
|
¨ã¦³¼ç¤OªÑ²¼ ¶R¶i µ¥«ÝÓ¤T¤¦~¬Oȱoªº §Ú±q°ò¨È¤½¥q¦¨¥ß´N«ù¦³ªÑ²¼¸g¹L13¦~ ¤~¦³¤µ¤Ñªº¦¨ªG ³o¤¤¶¡¸g¾ú¦h¤Ö¤ß±¡ªº°_¥ñ ¹ê¤£¨¬¬°¥~¤H¹D¦Õ ³£©ê«ùµÛ°í©wªº§Æ±æ. «ù¦³¯E¹© ¤]¬O¦b¥¼¤W¥«®ÉÔ´N¶R¶i ¤]©ê«ùµÛ«ù¦³3-5¦~ªº¥´ºâ.¦ý¤ß±¡¤ñ°ò¨È»´ÃP¦h¤F ¦Ü¤Ö¤£¥Î¼õ³o»ò¤[ªº®É¶¡! ¦U¦ìn¦³@©Ê-------¿ï¹ïªÑ²¼¨Ã@¤ß«ù¦³ ¬OÁÈ¿úªº¨}¤è!! |
|
|
·|û¡G¨ÏªÌ10136366 µoªí®É¶¡:2013/5/10 ¤U¤È 01:35:43²Ä 97 ½g¦^À³
|
ÃÙ¦P"´µ¯S¤j¤j"©Ò¨¥, ·|û¡G´µ¯S10135783 µoªí®É¶¡:2013/5/9 ¤U¤È 06:45:48 §ë¸êªÑ²¼,Á`¦³¨Ç¤£½T©w¦]¯À, ¦pªGOBI822¤w½T©w¦¨¥\,´N¤£¥i¯à°±¯d¦b³oÓ»ù¦ì ¦ôpTFDA³q¹L³Ì§Ö¤]n 3-5¦~,usa FDA approve ´N§ó¤[ ¦]¥xÆW²Ä¤T´ÁÁ{§É¸ÕÅçµ²§ô«á, ¤]n°µ²Îp¤ÀªR(¤j¬ùªá¥b¦~), ¥Ó½Ð·sÃĬdÅçµn°O¹Lµ{¤]¦Ü¤ÖÁÙn¥b¦~~1¦~, ©Ò¥H2016¦~¤W¥«ºâ¸û¼ÖÆ[·Qªk. °£«D, ´Á¤¤¤ÀªRªº²Îp¼Æ¦r·¥¦n, ¥ß¨è±ÂÅvµ¹°ê»Ú¤jÃļt, ¨º´N¤£®ø2¦~©¡®ÉªÑ»ù¥i¯à´N¤@¸¨R¤Ñ¤F. |
|
|
·|û¡G¦º©ê10136078 µoªí®É¶¡:2013/5/9 ¤U¤È 12:16:46²Ä 96 ½g¦^À³
|
²q·Q¤j¤j: ¨¯W¤F! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/5/9 ¤W¤È 11:59:02²Ä 95 ½g¦^À³
|
ªÌ¤j¤j¿n·¥ªººë¯« ¥O¤H·q¨Ø ¤p§Ì¥ý«eªº¬Ýªk ´N¥u¬O¤p§Ìªº¬Ýªk À³µL©Ò¿×¬O«D¹ï¿ù DIFICID ¥Ø«eÄÝ©ó¬ü°ê Optimer Pharmaceuticals ©Ò¾Ö¦³¤Îµn°O ³oÓ¤p§Ìª¾¹D Optimer Pharmaceuticals³Ìªì¬O¥Ñ±i¸³©Ò³Ð¥ß ²{¤¨¦ÑÁó©M±i¸³¤´¦³ªÑÅv ¥[¤W¥Ø«eµ¹¯E¹©¥N¾P ©Ò¥H¤p§Ì¦³"°ê¤H"ªº·Qªk ¤§«e¬F©²¬°¤F¹ªÀy¥xÆWªº¥Í§Þ·~·sÃĬãµo ¦Ó¦³µ¹¤©°·«O给¥Iªº¼úÀy±¹¬I §Ú¤£²M·¡½Ã¥Í¸pYµ¹DIFICID°·«O给¥I ¬O¥H°êÃÄ©Î¥~ÃÄ¬Ý«Ý DIFICIDY³Q¬F©²¥H¥~ÃÄ¬Ý«Ý µ¹¤£µ¹°·«O给¥I¬O¬F©²ªºµô¶qÅv Y¥H°êÃÄ¬Ý«Ý µ¹°·«O给¥Iªº¾÷·|´N¬Û¹ï´£°ª ±z¤S»¡ : ¡§¦p¦¹¨Ó§PÂ_, 822 ¥ç¦³¥i¯àÃþ¦üherceptin ¬O¸g¥Ñ½Õ¸`¤@ºØ§ÜÅé¨Ì¿à«¬²ÓM´C¤¶²ÓM¬r©Ê§@¥Î(antibody-dependent¡@cell-mediated¡@cytotoxicity¡FADCC)¨Ó±þ¦º¸~½F²ÓM. Y¬O¦p¦¹,´N»P¢ó¢é¤j¤j¤§«e¤å³¹©Ò´£ºÃ¼{¦³¹p¦P¤§³B¡¨ ³oÓ¤p§Ì´N¦³¨Ç¤£²M·¡¤F §Ú·Q±zªº·N«ä¬O °²¦pHerceptin©M OBI-822³£¬O¦P¼Ë§@¥Î¨Ó±þ¦º¸~½F²ÓM ¬°¦ó·|¦³25%»P60%¤§§O? ¤p§Ì«e±´¿»¡ ¨º¬O¤GªÌªº¼Ð¹v¤£¤@¼Ë ¤p§Ì²q·Q ¨ÅÀùªº²ÓM·íµM¤£¥u¥u¦³³o¨âºØ¦](¤À)¤l ¤]³\ÁÙ¦³¨ä¥L§ó´Îªº¦]¤l ¥u¬O²{¦bÁÙ¥¼µo²{ HER-2 »P Globo H ´N¬O¤w³Qµo²{ªº¨ÅÀù²ÓM¤Wªº¼Ð°O Herceptin¥u·|§ä¦³HER-2ªº²ÓM¨Ó§ðÀ» ¦ýHER-2¥¿±`²ÓM¤]¦³ ©Ò¥HHerceptinªº°Æ§@¥Î¤£¤p OBI-822¤]¥u»{±oGlobo H ¤~·|§ðÀ» HER-2 »P Globo H ¦s¦b¨ÅÀù²ÓM¤Wªº¤ñ¨Ò¤£¤@¼Ë ¤]´N³y¦¨¤ÏÀ³ªº¤ñ¨Ò¤£¦P ³o´N¬O¨âªÌ¦³25%»P60%®t²§ªºì¦]§a ¤p§Ì«D±M·~ ¬Ýªk©Î¦h»~ÂÕ ½Ð«ü±Ð ¤p§Ì¦³ÂI²Ö¤F °ò¥»¤W±z§Ú¤§¶¡ ¦³ÂI»{ª¾¤£¦P ¥H«áY¦³¤£¦P¬Ýªk ½Ðì½Ì¤p§ÌµLªk¤@¤@¦^À³ ÁÂÁ±zªº«ü±Ð ¤]ÁÂÁ¤j®a! |
|
|
·|û¡G¨ÏªÌ10136366 µoªí®É¶¡:2013/5/9 ¤W¤È 10:42:19²Ä 94 ½g¦^À³
|
DIFICID ¥Ø«eÄÝ©ó¬ü°ê Optimer Pharmaceuticals ©Ò¾Ö¦³¤Îµn°O, ½Ð¨£ DIFICID ¬ü°ê©xºô. http://www.dificid.com/ ¥B°·«O®Ö»ù¥Dn¬O©MÃÄ«~ªºÃÄ®ÄÀu¦H,¥ý¶i°ê®a¤W¥«»ù®æ»P¨ä¥LÄvª§«~¤W¥«»ù®æ¦³Ãö, ¸ò½Ã¥Í¸p¬O§_·|¦¬¦^°·«O®Ö»ùÀ³¬O§¹¥þµLÃö§a. |
|
|
·|û¡Gbill10135881 µoªí®É¶¡:2013/5/9 ¤W¤È 10:00:11²Ä 93 ½g¦^À³
|
ªÑ»ù°Ê¤F? °µ¦h°µªÅ¯u¬OµL¨¥! |
|
|
·|û¡GµL¦W10031736 µoªí®É¶¡:2013/5/9 ¤W¤È 09:47:56²Ä 92 ½g¦^À³
|
ªÑ»ù·|»¡¸Ü¡A°Ê¤F¡H |
|
|
·|û¡Gbill10135881 µoªí®É¶¡:2013/5/9 ¤W¤È 09:41:21²Ä 91 ½g¦^À³
|
¦Aµ¹²q·Q¤j¤j«öÓ¡§Æg¡¨!! ¦³¤j¤j±zªºµo¤å·í°µ¡y¤¤¬y¯¡¬W¡z µ½«v!! ¦ö§Ú¤@¯ë´¶³qªº¤p¤p´²¤á¡A ¤£¨ü¶Â·t±ªº¼vÅT!! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/5/9 ¤W¤È 08:54:59²Ä 90 ½g¦^À³
|
ÁÂÁ¤j®aªº«ü±Ð ¤p§Ì¦b¦¹Án©ú ¤p§Ì¤£¬OÂ\¾Ý¥xªº ¤p§Ì¥u¬Oµoªí¦Û¤vªº¬Ýªk¦Ó¤w ªÌ¤j¤j¦n¹³¥Î°µ¬ã¨sªºÄYÂÔºA«× ¨Ó¬Ý«Ý¤p§Ìªºµo¨¥ ½Ð±z»´ÃP¥H¹ï «¢! ¤p§ÌÁöµM¤£¤~ ¦ý¤p§Ìªºªº¦^À³¤å ¤wºÉ¶qn¨D¦Û¤v°µ¦³Å޿誺²q·Q Y¦³Åý¤j®a¬Ý¤£ºDªº¦a¤è ¤]½Ð¨£½Ì ¤U¦C¤p§Ì´N»¡©ú§Úªº«äºûÅÞ¿è ½Ð¤j®a«ü¥¿ ¬Ý¤F±zªº»¡©ú ¤p§Ìª¾¹D±z¥i¯à¬OÂåÃıM·~¤H¤h ¤p§ÌÁÂÁ±zªº«ü¾É ¤p§Ì»¡¦³±o¤£Àv¥¢¤§Á| ¥Dn«Øºc¦b¤U¦C«äºû ½Ã¥Í¸pY¬O¦]¬°DIFICID¬O°ê¤Hªº¤½¥q©Ò¬ãµo ¤~µ¹°·«O®Ö»ùªº Y¥¼¨ÓOPTIMER´«¤â¸gÀç«á ´NÄÝ«D°ê¤H¤½¥q(Y¤£¬O°ê¤H®³¤U¸gÀçÅv) Y¤S¤£Åý¯E¹©¥N²z¾P°â ®Ú¥»´N»P¡¨°ê¤H¡¨ªºn¥ó²æ¸` ½Ã¥Í¸p¬O§_·|¦¬¦^°·«O®Ö»ù ¬OӺü{ ¤p§Ì¹ï©óOBI-822¦b¥xÆWªºÁ{§É¦ôºâ ©Î¥¢¤§¼ÖÆ[ ³oÂI§Ú©Ó»{ ¦ý±zÁ|Ä«ªGªº³ø¾É ¹w¦ô¦b2016¤~¯à®³¨ìÃÄÃÒ ¤p§Ì¤£²M·¡¬O«ü¥xÆW©Î¬ü°ê ¨Ì·Ó¯E¹©¦b¥xÆWªºÁ{§É¸ÕÅç¸ê®Æ ¥¦ªº¡¨¸ÕÅç¹wp°õ¦æ´Á¶¡¡G2010-08-01 ¦Ü 2014-02-28¡¨ §Ṳ́£ª¾¬O§_·|©µ¿ð Y·Ó³oÓ¹w¦ô®É¶¡ ¤p§Ìªº±À¦ô À³ÁÙºâ¦X²z ¦Ü©ó¤Ó¤j¤jªºÆ[ÂI ¡§Á{§É¤@´Áªº¼Æ¾Ú¬O§_¥i¯à¥]¸Ë¹L ?¡¨ ¤p§Ì«D±M·~¤H¤h ¤U¦C»¡ªk¯ÂºéÓ¤H²q·Q OBI-822ªºÁ{§É¤@´Á¦Ü¤µ¤w¶W¹L15¦~ ¥¿¦nÅý§ÚÌÀ˵øOS ªº¾÷·| ³oÓ¡¨¥]¸Ë¡¨¦p¦ó©w¸q ·Q¥²¤½¥q¤£·|«§ïOSªº¼Æ¾Ú ¦ý±wªÌ¯à¦s¬¡¨º»ò¤[¬O¨Æ¹ê ¥u¬O³o¤¤¶¡¦³µL¥LºØªvÀø°Ñ»Pªº¥\³Ò §Ṳ́£ª¾¹D ¦]¬°±wªÌ¦b¦³¯e¯f¶i®i«á(¨Ò¦p´_µo©Î¤S²¾Âà)¥²©w¤S·|¦^Âå°|±µ¨üªvÀø ³o¤¤¶¡ªº¹Lµ{´N«ÜÃø»{©w¦óªÌ¬O©~¥\ªº ·íµM¨S¦³¯e¯f¶i®iªº±wªÌ ·í¥i»{¬°¬OOBI-822ªºÃÄ®Ä ²{¦b2/3´ÁÁ{§É³£¥HPFS¬°¥Dn¥Ø¼Ð Á{§É¤@´Áªº¼Æ¾ÚPFS 4¦~¶W¹L41% ¦n¶Ü? ¤j®a¥i¥H¸òºZ¾P¦WÃÄHerceptin¤ñ¸û ÁöµMOBI-822ªºÁ{§É¤@´Á¼Æ¾Ú ¦n¹³¤£¿ù ¦ý¤½¥q¨Ã¤£¥H¦¹¬°º¡¨¬ Á{§É2/3´Á ¤S¸û¤@´Á²¤¦³×¥¿ ¨Ò¦p ±N5¾¯§ï¬°9 ¾¯ ¤S»P¤ÆÃÄcyclophosphamide²Õ¦X ¨Ó¼W¥[¿Eµo§ÜÅ骺¯à¤O ÃĮĬO§_¦]¦Ó¼W¥[ ¤´«ÝÅçÃÒ ¤p§Ì¦b¦¹²q·Q «ª©ó±M·~¯Ê¥F ©ÎP²_¬°¯º¬` ½Ð¤j®a¬Ý¬Ý´N¦n ¤Å·í¯u ²¦³º¥¦³£¥u¬O¤p§Ìªº²q·Q ÁÂÁ¤j®a! |
|
|
·|û¡G§Ú§Ú§Ú10021927 µoªí®É¶¡:2013/5/9 ¤W¤È 08:13:15²Ä 89 ½g¦^À³
|
¦³¨Ç¤H§âªø½u·íµu½u¾Þ§@, ·QÁÈ»ù®t«o¤@¤£¤p¤ß³Q¬~¥X¥h¤F, ´N©¿µM¸õ¥X¨Ó«÷©R©ñ§QªÅ¡C ²q·Q¤j,¤j¥i¤£¥²¬°¦¹«Êµ§, ±zªº¨¥½×«D±`¦³¦Û¤vªº¤º®e, ¥iŪ©Ê«D±`°ª¡C «Ü§Æ±æ¯à¬Ý¨ì±z§ó¦hªºµo¨¥¡C |
|
|
·|û¡G¨ÏªÌ10136366 µoªí®É¶¡:2013/5/8 ¤U¤È 11:43:47²Ä 88 ½g¦^À³
|
²q·Q¤j»{¬°: "¤£ª¾±z¦³¨S¦³ºâ¹L OBI-822¦b¥xªºÁ{§É¤G´Á ¸g¾ú¦hªø®É¶¡ ´NÀòã¶i¤JÁ{§É¤T´Á ¦Ó¶i¤JÁ{§É¤T´Á¨ì²{¦b¤S¸g¹L¦h¤[ ¤p§Ì²q·Q Y©Û¶Ò±wªÌ¶¶§Q ¤]³\¤£¥Îªá¦n´X¦~§a ªp¥BOBI-822¬OTFDA§Ö³t¼f®Ö®×¥ó ¼f®Ö®É¶¡©Î³\¤]¤£¥Î¤Ó¤[ °²¦p¯à«Ü¶¶§Q®³¨ì¤W¥«³\¥i ©Î³\³o¦¸²{¼W«á´N¤£¥Î¦A¦VªÑªF¦ù¤â¤F(³o¬O¤p§Ì¦Û¤v¼ÖÆ[ªº·Qªk)" Ä«ªG¤é³ø©ó2012¦~12¤ë13¤é¥Z¥X¤j¼ÐÃD"·m¥þ²y200»õ¬ü¤¸¤j»æ ¯E¹©·sÃÄ«÷2016¦~¤W¥«", ¥ç½Ð¨£¥H¤Uºô§} http://www.appledaily.com.tw/appledaily/article/finance/20121213/34702323/ ²{¦b¬O2013¦~, ¶ZÂ÷2016¦~ÁÙ¦³3¦~, Y¥¼¨ÓDIFICIDªºÀ禬Äéª`¦³¥ô¦ó®t¦À, ¤£´N¥i¯àÄ~Äò»Ýn¿N3¦~ªÑªF¿ú¶Ü? ¦¹¬°¤p²L¨£, ½Ð°Ñ¦Ò. |
|
|
·|û¡G¤Óºò(±i)10135421 µoªí®É¶¡:2013/5/8 ¤U¤È 11:32:35²Ä 87 ½g¦^À³
|
§Ú·Q¦U¦ì¤j¤j¥XµoÂI³£¬O¦nªº,¶°«ä¼s¯q,¦hªÅ¨¥½×³£ok°Õ~¨ä¹ê¤j®a¤ß¤¤¦³£¦³¤@§â¤Ø,©ñ»´ÃPÅo!! ¦³¤H¦]¦¹«Êµ§´N¯uªºº¡¥i±¤.¦b³o¨ü¯qº¡¦h¤F. ¯E¹©¥¼¤W¥«®É´N¥W¤F,§Ú¹w©w¬Oµ¥¦~©³´Á¤¤¤~·|°µ¤U¦¸¶R½æ§PÂ_. ¦³½Ð¼ö¤ß¤j¤jÀ°¦£¸ÑŪ¥H¤U¼Æ¾Ú¬O§_¥i¯à¥]¸Ë¹L ? ±ß´Á¨ÅÀù¼Æ¾ÚÁÙ¦p¦¹Àu.©µªø¤£¥u¼ÆӤ몺¥Í©R? ¯E¹©²Ä¤@´ÁªºÁ{§É¹êÅç¨Ó¬Ý¡A¦³41%ªº¯f¤H¬Æ¦Ü¦s¬¡¶W¹L¤Q¦~ §Y¨Ï¤wÂಾªº¨ÅÀù¯f±w¤´¦³ªñ8¦¨¥i¦s¬¡¶W¹L4¦~¡C ¥B¥Ø«eÁ{§É¤W¤w°µ¨ì§Ö¨â¦ÊÓ¯f¤H(±N¦¬®×342),¤w¹L¥b¹F58%,©â¼Ë¼Æ«Ü°ª¤F. |
|
|
·|û¡G¨ÏªÌ10136366 µoªí®É¶¡:2013/5/8 ¤U¤È 11:23:59²Ä 86 ½g¦^À³
|
°w¹ï"²q·Q¤j"¹ï "KA¤j" ªº¦^À³, ¦Û¤v¦³¸û¤£¦P¬Ýªk, ½Ð参¦Ò. "²q·Q¤j"»{¬°: "DIFICID ¤µ¦~¯à¤£¯à¨ú±o°·«Oµ¹¥I ³o¤p§Ì·íµM¤£ª¾¹D OPTIMER´«¤â¸gÀç«á ·|¤£·|¦¬¦^¦Û¤v½æ ¤p§Ì·QÀ³¸Ó¤£·|§a ±z·Q ¥xÆW³o¤è±ªºÀç·~ÃB¥i¯à¤£¦h ¦ó¥²¤j¶O©P³¹ ¦Ó¥B´«¥N²z°Ó ´N¬O»P¥xÆW¯E¹©¤Á³Î ©Î³\¨ú±oªº°·«Oµ¹¥I¤]·|³Q¦¬¦^ ¬O±o¤£Àv¥¢¤§Á|" ¨ä¹ê, ÃÄ«~³c°âÅv³Qì¼t©Î³Q¨ÖÁÊì¼tªº¤½¥q®³¦^, ³o¦b¥~°ÓÃļt¬O¥qªÅ¨£ºDªº¨Æ. Á|¨Ò¨Ó»¡, Y¥~°Ó쥻¦b¥xÆW¨ÃµL¤À¤½¥q, ¥u¦³¥xÆW·í¦a¥N²z°Ó¨Ó¥N²zªx°â, ¦ýYì¼t¨£ÃÄ«~¦b¥xÆW³c°â¤£¿ù©Î¥»¨·QÂX®i¦æ¾P°Ï°ì¦Ó¦¨¥ß¦b¥x¤À¤½¥q¨Ó®³¦^³c°âÅv, ¥N²z°Ó©ó«´¬ù´Áº¡«á¬OµL¤O©Úµ´ªº. ¦AªÌ, Yì¼t³Q¨ä¥L¤½¥q¨ÖÁÊ, ¨ÖÁʤ½¥qY·Q¥Ñ¦Û¤v¦b¥x¤À¤½¥q©Î¥ÑÄÝ·Nªº¥N²z°Ó«·s®³¦^³c°âÅv, ¥ç¬O±`¨£²{¶H. ¦Ü©ó°·«O»ù¥Ó½Ð, ¸ê®Æ°ò¥»¤W³£¬O¥Ñì¼t´£¨Ñ, Y©¡®É·Qn®³¦^³c°âÅv, «hì¼t©Î¨ÖÁʤ½¥q¥ç·|¦V½Ã¥Í¸p¦P®É¥Ó½Ð´£¥X´«·Ó¿ì²z´N¥i»´©ö¸Ñ¨M, ²z½×¤W¨ÃµL"±o¤£Àv¥¢¤§Á|"ªººÃ¼{. |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/5/8 ¤U¤È 10:30:09²Ä 85 ½g¦^À³
|
·PÁÂka¤j µ¹¤j®aªº¸ê°T Åý¤p§Ì¤S¦h¤F¨Ç´¼¼z ¤£²M·¡ka¤j«e¤å¬O»¡Àù¯gªvÀø¬Ì]³£«ÜÄê ÁÙ¬O»¡ FDA §âÃö¤£¤O? ¤]³\ka¤jµù¥U¸¹½X¦b¤p§Ì¤§«á ¤§«e¤p§ÌªºJî¤ ±z¥i¯à¨S¬Ý¨ì ¨º¤]¨SÃö«Y ±z¹ï¤½¥qªº½èºÃ ¤p§ÌÁö«D¤½¥qû¤u ¦ý¤p§Ì¨¬°¤½¥q¤p¤pªÑªF ¤]¦Û¤£¶q¤O¬°¤½¥q®Â½Ã¤@¤U ±z°Ý : ¡§DIFICID ¤µ¦~®³¨ì¥i¤W©ï±ªº°ª°·«O»ùªº¾÷²v? ªp¥B¬ü°êOPTIMER Y¤@¥¹³Q¥æ©ö½æ±¼(¥i¯à©Ê°ª),¨º DIFICID ªº¾P°âÅv¬O§_´N·|³Q¦¬¦^. ¨º¤£´N¥¼¨Ó´X¦~´N·|µL¥ô¦ó²£«~À禬, ¤§«á¥u¬O¿NªÑªFªº¿ú¤ÎªÑ¥Á§ë¸êªº¿ú. .¡¨ ¤p§Ì»{¬° : DIFICID ¤µ¦~¯à¤£¯à¨ú±o°·«Oµ¹¥I ³o¤p§Ì·íµM¤£ª¾¹D OPTIMER´«¤â¸gÀç«á ·|¤£·|¦¬¦^¦Û¤v½æ ¤p§Ì·QÀ³¸Ó¤£·|§a ±z·Q ¥xÆW³o¤è±ªºÀç·~ÃB¥i¯à¤£¦h ¦ó¥²¤j¶O©P³¹ ¦Ó¥B´«¥N²z°Ó ´N¬O»P¥xÆW¯E¹©¤Á³Î ©Î³\¨ú±oªº°·«Oµ¹¥I¤]·|³Q¦¬¦^ ¬O±o¤£Àv¥¢¤§Á| ¤£ª¾±z¦³¨S¦³ºâ¹L OBI-822¦b¥xªºÁ{§É¤G´Á ¸g¾ú¦hªø®É¶¡ ´NÀòã¶i¤JÁ{§É¤T´Á ¦Ó¶i¤JÁ{§É¤T´Á¨ì²{¦b¤S¸g¹L¦h¤[ ¤p§Ì²q·Q Y©Û¶Ò±wªÌ¶¶§Q ¤]³\¤£¥Îªá¦n´X¦~§a ªp¥BOBI-822¬OTFDA§Ö³t¼f®Ö®×¥ó ¼f®Ö®É¶¡©Î³\¤]¤£¥Î¤Ó¤[ °²¦p¯à«Ü¶¶§Q®³¨ì¤W¥«³\¥i ©Î³\³o¦¸²{¼W«á´N¤£¥Î¦A¦VªÑªF¦ù¤â¤F(³o¬O¤p§Ì¦Û¤v¼ÖÆ[ªº·Qªk) ±z¤S»¡ : ¡§¦p¤åÄm¥iª¾, Herceptin ªºÃIJz¾÷Âà¬OÂÇ¥ÑADCC(antibody-dependent cell-mediated cytotoxicity; §ÜÅé¨Ì¿àªº²ÓM¤¶¾É¤§²ÓM¬r©Ê§@¥Î)¨ÓºR·´¨ÅÀù²ÓM, ¥ç¬O«ü¤wªí¹FIgG Fc ¨üÅ骺¦ÛµM±þ¤â²ÓM¡A³q¹L»P¤w¨Æ¥ýµ²¦X¦b¨ÅÀù²ÓMªí±ªºIgG §ÜÅ骺Fc ¬qªº¦Aµ²¦X¡A¶i¦Ó±þ¶ËºR·´³o¨Ç¨ÅÀù²ÓM¡CY822¬O¬Û¦PÃþ¦ü¾÷¨î, ¨º´N¤£¤Óºâ³Ð·s¬ð¯}·sÃÄ? ¨º»ò¤S¦p¦ó¥iÃÒ©ú¦b¤j¦h¼Æ¨ÅÀù±wªÌ¥i¦³®Ä? ²¦³ºHerceptin ¤]¥u¹ï20~30% ªº ¨ÅÀù¯f¤H¦³®Ä(HER2+) .¡¨ ¤p§Ì»{¬° : ¤p§Ì¦b¤TÁ`ªººô¯¸ §ä¨ì¹ïHerceptinªº¤¶²Ð ¨ä¤¤¦³ÃöÁ{§É¸ÕÅ窺¼Æ¾Ú¦p¤U ¡§¦@¦³235¦ì¯f±w±µ¨ü¤ÆÀø¥[Herceptin,234¦ì¯f±w±µ¨ü¤ÆÀø;«eªÌªvÀø«á¦Ü¯e¯f´c¤Æ¤§¤¤¦ì®É¶¡¬°7.6Ó¤ë,¦Ó«áªÌ¶È¬°4.6Ó¤ë(p=0.001);¦bAC+ Herceptin³o¤@²Õ¬°8.1Ó¤ë, AC³o¤@²Õ¬°6.1Ó¤ë(p=0.0003); paclitaxel + Herceptin³o¤@²Õ¬°6.9Ó¤ë, paclitaxel³o¤@²Õ¬°3Ó¤ë(p=0.001)¡C¦b½w¸Ñ²v¤è±,¤ÆÀø¥[Herceptin³o¤@²Õ§¹¥þ½w¸Ñ²v¬°8%,³¡¥÷½w¸Ñ²v¬°41%,Á`½w¸Ñ²v¬°49% (95% «H¥Î°Ï¶¡:42~55%);¦Ó¤ÆÀø³o¤@²Õ§¹¥þ½w¸Ñ²v¬°5%,³¡¥÷½w¸Ñ²v¬°27%,Á`½w¸Ñ²v¬°32% (95% «H¥Î°Ï¶¡:26~38%),¨âªÌ¤ñ¸û©Ò±o¤§pȬ°0.0002¡C¡¨ ³oÓ¼Æ¾Ú ½Ð¤j®a¦Û¦æ¸ÑŪ ±z»{¬°¡¨Y822¬O¬Û¦PÃþ¦ü¾÷¨î, ¨º´N¤£¤Óºâ³Ð·s¬ð¯}·sÃÄ? ¨º»ò¤S¦p¦ó¥iÃÒ©ú¦b¤j¦h¼Æ¨ÅÀù±wªÌ¥i¦³®Ä?¡¨ OBI-822ÁÙ¦bÁ{§É¤¤ ©|«Ý½T»{ÃÄ®Ä «¢! °²¦p³o¬O«Ü·s³Ðªº§Þ³N ¤p§Ìµ´¹ï¤£´±½ä ¦]¬°«Ü®e©ö¥X§½ ¤£ª¾¹DÃIJz¾÷Âà ¤]¨S¼Æ¾Ú´£¨Ñ°Ñ¦Òªº ¤p§Ì¤]¬O«O¦uªº ±z¤]Âà¸ü«Ü¦h¤å³¹ ¤]¦³Ãö©ó§K¬Ìªº ¬Ì]ªº«ÂI ¦b©ó¥´¤J¤HÅé«á¯à¤£¯à¤Þµo§K¬Ì¤ÏÀ³ ¶i¦Ó§ä¨ì¼Ðªºª«¤©¥HºR·´ Herceptinªº¼Ð¹v¬O HER-2 (20~30%ªºBC±wªÌ¨ã¦³ ©Ò¥H¥u¹ï³o¨Ç±wªÌ¦³®Ä) OBI-822ªº¼Ð¹v¬O ¨ã¦³Globo H ªºÀù²ÓM °²¦p¬O60%ªºBC±wªÌ¨ã¦³(¤½¥qªk»¡¸ê®Æ) ¤]´N¥u¹ï³o¨Ç±wªÌ¦³®Ä ¥t¥~¥i¯àÁÙn¬ÝGlobo H ¦b¨ÅÀù²ÓMªºªí²{¶q¦Ó©w ¤¤¬ã°|§ÞÂ઺OBI-833¬O¥Î¨ÅÀù·í¬ã¨s¹ï¶H OBI-833 ¥i¦P®É°w¹ï¨ÅÀù²ÓM¤¤ªº¤TÓÁÞ¤À¤l·í¼Ð¹v ¥i¿×¦h¼uÀY¬Ì] ¯E¹©¦b 3/7 ªºªk»¡¸ê®Æ¤¤ ´¿´£¤Î ¡§ 91.8% Globo H expression in Pancreatic Cancer¡§ ¡§ 94.2% Globo H expression in MBC Subjects (OBI-822-001) ¡§ ³o¨Ç¸ê®Æ§i¶D§ÚÌ ¦³¥i¯à OBI-833 ¹ï¯ØŦÀù±wªÌªº¤ÏÀ³²v¬O 91.8% ¹ï MBC ±wªÌªº¤ÏÀ³²v¬O94.2% ·íµM³o¬O²z½× ¹ê»Ú±¡ªp¤´«ÝÁ{§ÉÅçÃÒ ³o¬O¤@Ӧۥѽ×zªºªÅ¶¡ ´Á«Ý¤j®a²z©Ê°Q½× ¤p§Ìªº¨¥½×¨S¦³n¼vÅT½Ö ¨Æ¹ê¤W¤]¼vÅT¤£¤F½Ö ¤p§Ì»¡¹L ªÑ»ù¤£¬O´²¤á¨M©wªº ¨ì¥Ø«e¬°¤î ¤p§ÌÓ¤H»{¬°¤½¥q¬O«Üµ½«Ý¤pªÑªFªº §Æ±æ¤½¥q«O«ù³oÓ²z©À Ä~Äò§V¤O Åý¤ä«ù¤½¥qªºªÑªF¸òÀH¤½¥qªº¸}¨B¦¨ªø ¯¬¤j®a³£¤jÁÈ ¥H¤W¨¥½×¯Â¬°²q·Q ½Ð¨Ì±z¦Û¤vªº¦hªÅ§PÂ_¶i¥X ÁÂÁ±z! |
|
|
·|û¡Gka10136363 µoªí®É¶¡:2013/5/8 ¤U¤È 02:33:55²Ä 84 ½g¦^À³
|
Àù¯g¬Ì]ÅSÀÆ¥ú? --> ¥u©µªø¼ÆӤ몺¥Í©R? ²Ä¤@ÓªvÀøÀù¯gªº¬Ì]©ó2010¦~®Öã¤W¥«¡A¨ä¥L¬¡¤Æ§K¬Ì¨t²Î¹ï§Ü¸~½FªºÃĪ«¤]¦b¬ãµo¤¤¡A¨ä¯à»P²{¦³Àøªkµ²¦X¡A§ó¦³®Ä¹ï§ÜÀù¯g¡C ¼Æ¤Q¦~¨Ó¡AÂå¥Í¥Dn´£¨ÑÀù¯g¯f¤H¤TºØÀøªk¡G¤â³N¡B¤Æ¾ÇÀøªk©M©ñ®gÀøªk¡C¡]¦³¨ÇÀù¯g¦s¬¡ªÌ©ú¥Õ«ü¥X³o¤TºØ¯}Ãa©ÊÀøªk¡A¬O¡u¶Ã¤Á¡B¤U¬r©M¿U¿N¡v¡C¡^¦h¦~¨Ó«ùÄò§ï¨}³o¨Ç§Cºë·Ç«×ªºÀøªk«á¡A¸û¬°ÄY«ªº°Æ§@¥Î¤wÀò±o§ïµ½¡AÀø®Ä¤]ÅãµÛ´£¤É¡CÁÙ¦³¹ñ·sªº¼Ð¹vÃĪ«¡]¨Ò¦p¶PÀù¥©M°ò§Q§J¡^¡A¥i¥H¥Î¨ÓªvÀø´XºØ¯S©wªºÀù¯g¡C30¦h¦~¨Ó¡A«I¥Ç©ÊÀù¯gªº¤¦~¥§¡¦s¬¡²v¤w¸g±q55%´£¤É¨ì66%¡A¤£¹L¡A«Ü¦hÀù¯g¦s¬¡ªÌÁÙ¬OµLªk¦w¨É¤Ñ¦~¡C ªø´Á¥H¨Ó¡A¬ã¨s¤Hû¬Û«H¥un§ä¨ì¤èªk¡A¨ë¿E¨Åé¦Û¨ªº§K¬Ì¨t²Î§ó¦³®Ä¹ï§Ü´c©Ê¸~½F¡A´N¯à¤j´T´£¤ÉÀù¯g±wªÌªº¦s¬¡²v¡A¦Ó¥B¤£·|²£¥ÍÄY«°Æ§@¥Î¡C¦ý¬O¼Æ¤Q¦~ªº§V¤O¡A¥u´«¨Ó¤£Â_ªº¥¢±Ñ¡CÁ|¨Ò¨Ó»¡¡A1980¦~¥N¹ï©ó§K¬Ì¨t²Î¤À¤l¤zÂZ¯À©ê«ù¹L°ª§Æ±æ¡A¥H¬°¯à¤Þµo¨Å騾¿m¯à¤O¨ÓªvÀø¥þ³¡©Î¤j³¡¥÷Àù¯g¡A¦b´X¦~ªº¬ã¨s«á¡A¹Ú·Q¯}·À¡C¥Ø«e§Ú̪¾¹D¤zÂZ¯À¦³¤@©wªº®ÄªG¡A¦ý¤£¬O¹L¥h©Ò¥H¬°ªº¸UÆF¤¦¡C21¥@¬öªº²Ä¤@Ó10¦~¡A²³¦h§Q¥Î¤£¦PºØ¬Ì]¬ÛÃöµ¦²¤¶i¦æªºÁ{§É¸ÕÅç¡A¦ü¥G¨S¦³¤@Ó¦³®Ä¡Cµo®i´Á«Ý¤w¤[¡B¯à¹ï§Ü¤£¦PÃþ«¬¸~½Fªº³q¥ÎÀøªk¡A¬Ý¦ü«D±`Ãø¥H¹ê²{¡C ¥Ø«e¹Ú·QÁöµM©|¥¼¹ê²{¡A¦ý¬O¦b³ê¿ô§K¬Ì¨t²Îªº§V¤O¹Lµ{¤¤¡A¨«¿ù¸ô©M¨«¤J¦º«Ñªºª¬ªp¥i¯ànµ²§ô¤F¡X¡X2010¦~®L¤Ñ¡A¬ü°ê¹«~¤ÎÃĪ«ºÞ²z§½¡]FDA¡^®Öã¤F²Ä¤@ÓªvÀøÀù¯gªº¬Ì]¡A¦W¬°Provenge¡CProvengeÁöµMµLªkªv¡Àù¯g¡A¤£¹L¦P®Éµ¹¤©¶Ç²Îªº¤ÆÀø¡A¤wÅý¼Æ¦Ê¦WÄáÅ@¸¢Àù¯g¥½´Á±wªÌ"©µªø¼ÆӤ몺¥Í©R"¡C ¬ì¾Ç®a¦b«·sÀ˵ø§K¬Ì¨t²Î¦p¦ó¹ï§Ü¸~½F²ÓM¡A¥H¤Î¸~½F¦p¦ó¹ï§Ü§K¬Ì¨t²Î§ðÀ»ªº´XÓ°ò¥»°²³]«á¡A¤~Àò±o³oÓ¥¿±ªºÂà§é¡C¥Ø«eÀù¯g¬ã¨s¤Hû¹ï©óµo®i¥X±M¤@©Ê¬¡¤Æ§K¬Ì¨t²Îªº¥þ·sÀøªk¡A©ê«ù¼f·V¼ÖÆ[ªººA«×¡C·sÀøªk¥i¯à¥u·|³y¦¨Ãþ¦ü·P«_¯gª¬ªº°Æ§@¥Î¡A¥i¥H°µ¬°¤â³N¡B¤Æ¾ÇÀøªk©M©ñ®g½uÀøªk¥~¡AªvÀøÀù¯gªº¥t¤@ºØ¿ï¾Ü¡C |
|
|
·|û¡Go10135877 µoªí®É¶¡:2013/5/6 ¤U¤È 04:08:39²Ä 83 ½g¦^À³
|
ÁÂÁ²q·Qªºªº©ú¥Ü,·sÃĤ½¥q«Ü¦h®ø®§©Mµ¦²¤©¹©¹¯µ¦Ó¤£«Å,»Ýn"²q·Q"ªº, ¤´§Æ±æ²q·Q¤j©¹«á¯à¦h¦h¯d¨¥«ü±Ð |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/5/6 ¤U¤È 12:17:29²Ä 82 ½g¦^À³
|
©êºp! o ¤j ¤]³\¬O¤p§Ì¼g±o¤Ó§t½k Åý±z¬Ý¤£¥X¨Ó ¤½¥qºô¶ªº»¡©ú ¤p§Ì§â×¥¿«e«áªº¤å¦r Âà¸ü©ó«á " ¦×¬r±ìµß¯À¬°¤@ºØ°ª§Q¼íªº²£«~¡A¨C²~°â»ù¬ù300¬üª÷¡A¨äÀò§Q»ù®t¦ôp¤j©ó80¢H¡C¥»¤½¥q³z¹L¦Û¦æ¬ãµo¦×¬r±ìµß¯À¥Í²£§Þ³N, ªì¨Bµ²ªG¦X¥G¼Ú¬wÃĨå³W½d¡C §Ú̥ثe¤w¶}©l©ó¦Ë¥_¥ÍÂå¶é°Ï¿³«ØP3¹êÅç«Ç¤Î°w¾¯¼t¡AµÛ¤â»s³yGMP²£«~¥H¨ÑÀ³°Êª«¸ÕÅç¤ÎÁ{§É¤HÅé¸ÕÅç¡C¹wp¦b2017¦~©ó¥xÆW¶q²£¨ú±o»{ÃÒ«á¶}©l¾P°â¡C¯E¹©¥Í§Þ¾ÌÂǧ޳N¤WªºÀu¶Õ¡A¥[¤W¦w¥þ¤Î¦³®Äªº«~½è¡A¨Ï¦×¬r±ìµß¯À¥Íª«¬Û¦ü©ÊÃĪ«»ù®æ¥i°§C40-60%¡A·¥¨ãÄvª§¤O. ¤@¥¹²£«~¤W¥«¥²¯à¬°¤½¥q³Ð³y³Ì¤j§Q¼í " ×¥¿¬° " ¦×¬r±ìµß¯À¬°¤@ºØ°ª§Q¼íªº²£«~¡A¨C²~°â»ù¬ù300¬üª÷¡A¨äÀò§Q»ù®t¦ôp¤j©ó80¢H¡C¥»¤½¥q³z¹L¦Û¦æ¬ãµo¦×¬r±ìµß¯À¥Í²£§Þ³N, ªì¨Bµ²ªG¦X¥G¼Ú¬wÃĨå³W½d¡C §Ú̪ºµ¦²¤¹Ù¦ñ¥Ø«e¤w¶}©l©ó¦Ë¥_¥ÍÂå¶é°Ï¿³«ØP3¹êÅç«Ç¤Î°w¾¯¼t¡AµÛ¤â»s³yGMP²£«~¥H¨ÑÀ³°Êª«¸ÕÅç¤ÎÁ{§É¤HÅé¸ÕÅç¡C¹wp¦b2017¦~©ó¥xÆW¶q²£¨ú±o»{ÃÒ«á¶}©l¾P°â¡C¯E¹©¥Í§Þ¾ÌÂǧ޳N¤WªºÀu¶Õ¡A¥[¤W¦w¥þ¤Î¦³®Äªº«~½è¡A¨Ï¦×¬r±ìµß¯À¥Íª«¬Û¦ü©ÊÃĪ«»ù®æ¥i°§C40-60%¡A·¥¨ãÄvª§¤O. ¤@¥¹²£«~¤W¥«¥²¯à¬°¤½¥q³Ð³y³Ì¤j§Q¼í " ¤]³\¤½¥q·íªì»{¬° "§ÚÌ"¬O¥]§t¤½¥qµ¦²¤¹Ù¦ñªºÁ`¬Aµü ©Ò¥H¥u¥Î"§ÚÌ"¤@µü¥Nªí ²{¤µ¤½¥q±N¤§§ï¬°"§Ú̪ºµ¦²¤¹Ù¦ñ" ´Nª½±µ¼á²M¥~¤HªºJ«ä¶Ã·Q ¤@¯ë¦Ó¨¥ ¤½¥qÀ³¤£·|ª`·N¦p¦¹§j¤ò¨D²«ªº²Ó·L³B ¬°¦ó¤½¥q·|°µ¦p¦¹×§ï Ãø¹D¬O¦]¬°¦³ª©±ªº¤j¤j¥h¹q¸ß°Ý¤½¥q©ÒP ¤p§Ì²q·Q ©Î¦³³oÓ¥i¯à ¤]³\¤p§Ì¥H«á´N±o¤Ö»¡¤@ÂI¤F ÁÂÁ¤j®a! |
|
|
·|û¡Go10135877 µoªí®É¶¡:2013/5/6 ¤W¤È 10:41:36²Ä 81 ½g¦^À³
|
½Ð°Ý²q·Q¤j,"²£«~»P¬ãµo"¤¤¬Y¶µ²£«~ªº»¡©ú ¼W²K¤F´XÓ¦r ¬O¦b¨º¸Ì¼W²K¤F¤°»ò¦r©O,§Ú¬Ý¤£¤Ó¥X¨Ó,¥i¥H©ú¥Ü¶Ü? |
|
|
·|û¡Gªüªê10136308 µoªí®É¶¡:2013/5/6 ¤W¤È 10:12:30²Ä 80 ½g¦^À³
|
¬Ý¤F¤j®aºëÅPªºµo¨¥ ±Í¤Hı±o®É¦b¨S¦³¦A¸m·J¤§³B ·Pı¯u¬O¨ü¯q¨}¦h°Ú! ¬Q±ß©¿µM·Q°_ ¦b¬ù20¦~«e¬Ý¹L§@®aݦò±Ð©~¤h¶¾¶¾ªºµÛ§@{ÁI©w¤Ñ²´³q¤§¹êÅç} ¸Ì±¦³§Ç³N¤@¨Ç¨Æ±¡ ºKn¦p¤U: Ãö¥ý¥Í»P§Ú¬Oªì·|¤£¤[¡A¦ý¬O§Ú¿h¨£¥L¦³«s¶ËµL¤ñªº¹ª¬Ö¤§µh¡C¥L°Ý¦¹»y¡A¥¿¬O¤ß¦³¾lµh¡A¤S¤ß¦s·O´d¡A¬ß±æ¥@¤W¦AµLÀù¯g¯eW¡C §Ú·P°ÊµL¤w¡A³¬¥Ø¨D¦ò½ç§Ú±o¨£¡A§Ú¨£¦ò¥ú°{°{¡A²{¥Ü¥X¤@Ӧʾl¦~«áªº¦~¥N¤é¤l¡A¤Î¤@Ó^¤å·s¦r¡C¬O¥Üª¾¨ì®É·|¦¨¥\©ó¤@ºØ§ï³yDNA¨Ï¤§²£¥Í§K¬Ì¤O¶qªº¥Íª«¤uµ{¬ì¾ÇÃĪ«¡A¨Ï²ÓM®ÖªºDNA¦Û°Ê®ø°£ÅܺAµo®iªº²ÓM¡C ¦b®y¦U¤H³£°O¤U§Ú©ÒÁ¿¥X¦ò¥Üªº¦r¤Î¦~¥N¡A¤j®a³£»¡¡A³oºc·Q«Ü·s¿o¡AÂ_¤£¬O¥¼¾Ç¬ì¾Çªº§Ú©Ò¯àÁr³yªº¡C ------³o¬O¶¾¶¾©~¤h©ó¬ù30¦~«e©ÒÁ¿¥X¨Óªº. ¥¼§¹ «ÝÄò! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/5/6 ¤W¤È 08:57:00²Ä 79 ½g¦^À³
|
¹ï¤£°_! ¦U¦ìª©±ªº¤j¤jÌ ¤p§Ì¥ý«e¼g¤F´X½g ¤p§Ì®Ú¾Ú½Ñ¦hºô¸ô°T®§©Ò°µªº²q·Q ³o¨Ç²q·Q©Î¦³²q´ú¤½¥q¥¼¨ÓÀç¹Bªº§G§½ ¦ý³o³£¬O¤p§ÌÓ¤H¤Ñ¯uªº·Qªk °²¦p³o¨ÇJvÅT¤F±z ©Î¹ï¤½¥q³y¦¨§xÂZ ¤p§Ì¦b¦¹¦V¤j®aPºp ¤p§Ì·|¦b¦¹¦V¤j®a¹Dºp ¬O¦]¬°¤p§Ì¬Q±ß¦b¤½¥qªººô¶ µo²{¤½¥q¦b"²£«~»P¬ãµo"¤¤¬Y¶µ²£«~ªº»¡©ú ¼W²K¤F´XÓ¦r ¬Q±ß¤p§Ì¥E¬Ý¥H¬°¦Û¤v¥H«e¦Ñªá²´¬Ý¿ù ¤£¹L¹ï·Ó¤p§Ì¥ý«eªºÂà¸ü ªº½T¦³°µ¤p×¥¿ ©Î³\¤½¥q·íªì"µL¤ß"ªº»¡©ú «o³Q¤p§Ì"¦³¤ß"¦a¸ÑŪ ¤p§Ì¦b¦¹¦A¦V¤½¥q»¡Án¹ï¤£°_ ¦Ó·íªì®Ú¾Ú³o¨Ç©Ò°µªº²q·Q ·íµM´NÄÝÂ÷ÃЪº¿ù»~ ´N½Ð¤j¤j̤@¯º¸m¤§§a ¦A¦¸»¡Án©êºp ÁÂÁ¤j®a! |
|
|
·|û¡Gªüªê10136308 µoªí®É¶¡:2013/5/2 ¤U¤È 12:11:17²Ä 78 ½g¦^À³
|
¤£ª¾¹D¤j®a¦³¨S¦³ª`·N¨ì ¦b¤Ñ¤UÂø»x²Ä516´Á¸Ì±ªº´I»¨+¬ì¾Ç®aªºªÑÅv´_¤³°O ¸Ì±±i©À·O¸³¨Æªøz»¡¯E¹©ªÑÅvª§¦h¾ÔªºÅåÀI¨ë¿E ¥L´£¨ì:¹L¨â¤T¦~¡An§ä¤j¾Éºt§õ¦w§â³oÓ¬G¨Æ©ç¦¨¹q¼v¡C ÁöµM³o¬Oª±¯º¸Ü ¦ý¬O¬°¦ó¬OÁ¿¨â¤T¦~? ³o¨ä¤¤¬O§_¦³±o²q·Q? ¨þ¨þ! |
|
|
·|û¡G¦º©ê10136078 µoªí®É¶¡:2013/4/30 ¤W¤È 10:13:07²Ä 77 ½g¦^À³
|
¬Ý¨Ó¶È¥u¬O¤î¶^¦Ó¤w ÁÙ¦b¿i¤H... |
|
|
·|û¡G¦º©ê10136078 µoªí®É¶¡:2013/4/30 ¤W¤È 09:11:08²Ä 76 ½g¦^À³
|
¦³¤î¶^ªº¸ñ¶H |
|
|
·|û¡G§Ú§Ú§Ú10021927 µoªí®É¶¡:2013/4/29 ¤U¤È 02:42:33²Ä 75 ½g¦^À³
|
¯E¹©»¡n¼W¸ê¨º¤@¤ÑªÑ»ù¬Oº¦ªº®@! ¨ä¹ê¨ä¥Lªº·sÃĪѴNºâ¶^¨ì0§Ú³£¤£·|·N¥~, ¦ý¬O³o¤ä´Nºâº¦¨ì10000§Ú¤]¨Ã¤£·N¥~¡C ¤£¥²ÀHªÑ»ù°_»R¡C ¶^?«Ü¦n§r!¶^§ó¦h§ó¦n,¨D¤§¤£±o... |
|
|
·|û¡Go10135877 µoªí®É¶¡:2013/4/29 ¤U¤È 02:23:01²Ä 74 ½g¦^À³
|
¥x·LÅé°ò¨È,¥«³õ¹w¦ô¤µ¦~·|ÁÈ¿ú,µ²ªG«o»Ýn¼W¸ê,ªí¤µ¦~¥i¯à¤£·|ÁȪº¾÷·|¤j,©Ò¥H¤U±þ¤j¶^ ,¯E¹©¥«³õ¹w¦ô¤µ¦~¤´Á«·l¦Ó¿ì²{¼W,¦X¥G¥«³õ¹w´Á©Ò¥H¶^¤ñ¸û¤Ö |
|
|
·|û¡G¦º©ê10136078 µoªí®É¶¡:2013/4/29 ¤U¤È 12:18:28²Ä 73 ½g¦^À³
|
¥Ñ©ó¥ý«e¥x·LÅé¿ì²z²{¼W1000¸UªÑ¡A¨CªÑ¼Èq298¤¸¡AªÑ»ùªí²{¤]±ó¦u²{¼W»ù¡A¨Ã«ùÄò¨«³n¡A¤]¥O¥«³õ¾á¼~¡A°ò¨È¤½§i¿ì²z²{¼W«á¡AªÑ»ù¨«¶Õ¬O§_±N«ÁÐ¥x·LÅéÂÐÂá¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/4/29 ¤U¤È 12:09:53²Ä 72 ½g¦^À³
|
°ò¨È«ç»ò¤F? ¦³Äw½X°ÝÃD¶Ü ÁÙ¬O¶^¯}¾ã²z¥¥x¤Þµo§Þ³N¬£ªº½æÀ£ ÁÙ¬O...? ³o¨Ç¤½¥q¤S¤£¬Oµ²«ô¥S§Ì ¬°¦ó¦Ñ¬O·R¬ÛÀH ¤p§Ì¦³ÂI°·§Ñ¤F èè§Ñ¤F©M¤j®a¤À¨É ¤j®a¦³¨Sµoı OBI-822³ºµM©M¤ÆÀøÃÄcyclophosphamide(§C¾¯¶q)¦X¨Ö¨Ï¥Î «ÜÄAÂФp§Ì³oÓªù¥~º~ªº·Qªk ¤p§Ì¥E¬Ý¤]¦Ê«ä¤£¸Ñ ª½¨ìY ÀY¤j¤j¥s¤p§Ì¥h¾\Ūªº¨º½g³ø§i ¤~Àò¸Ñµª ¨º½g³ø§i¬O°w¹ï¦UºØ§Üì»s¦¨ªº¬Ì] °µ¨t¦C¥Bºî¦X©Êªº±´°Q ¨ä¤¤¹ï©óºÒ¤ô¤Æ¦Xª«·í§Ü쪺¬Ì] ¼g¹D " The results reported to date suggested that such vaccines seem to be the most promising in inducing immunological responses if they were used in combination with cyclophosphamide and stem cell rescue. " ¦³®Éԥ䶳q±`ÃÑ ¥h²q´ú±M·~ªº¨Æª« ¯uªº¬O¤@¥ó¦MÀIªº¨Æ |
|
|
·|û¡GµL¦W10031736 µoªí®É¶¡:2013/4/29 ¤W¤È 11:13:12²Ä 71 ½g¦^À³
|
170áH |
|
|
·|û¡G¦º©ê10136078 µoªí®É¶¡:2013/4/29 ¤W¤È 11:03:16²Ä 70 ½g¦^À³
|
¥Í§ÞªÑ«®À... |
|
|
·|û¡G¦º©ê10136078 µoªí®É¶¡:2013/4/29 ¤W¤È 09:40:36²Ä 69 ½g¦^À³
|
Ĺ¹L°ò¨È«o¨S¦³¶}¤ßªº·Pı... |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/4/29 ¤W¤È 07:49:53²Ä 68 ½g¦^À³
|
£~£~¤j ¤p§Ì¤]´¿¨ìÃþ¦üªº³¡¸¨®æ¥h§ä´Mµïµ·°¨¸ñ ¬Ý¨ì¦³¤H¯uªº«Ü¨¯W¦a¥Î¼Ý¤O¹ï§Ü §Æ±æ¯E¹©ªº·sÃįà¦p·Q¹³¤¤ªº®ÄªG ¦¤é¤W¥« ³yºÖ¦³»Ýnªº¤H ¤p§Ì´X¥G¤Ñ¤Ñ³£¥hºC¶]¹B°Ê ¦³¤ÑÅ¥¨ì¨âÓ¤j©j(¤j¬ù±µªñ70·³ )¦b½Í¯E¹© ¦ý¦oÌ¥u½ÍªÑ»ù ¨S¦³½Í¤Î¨ä¥L¦³Ãö¯E¹©ªº°T®§ ¥»·Qª½±µ½Ð°Ý¦oÌ ¦ó¨Óªº°T®§Åý¦oÌ¥h¶R¯E¹© ¦ý¤S§@½} ¨Ì¤p§Ì§PÂ_ ¦b§Ú̶m¤U¦a¤è ³oÓ¦~¬öªº¤j©jÀ³¤£·|¸g±`¥Î¹q¸£¬d¸ê®Æ ¦ý¤p§Ì·Q¨ì §Ú̪þªñ¤]¦³¤@®a¯E¹©Á{§É¸ÕÅ窺Âå°| ¬O§_¬O±q¿ËªB¨ºÃäÅ¥¨ì¯E¹©ÃĮĪº®ø®§ Åý¦oÌ¥h¶R¯E¹© ¤@¯ë¨Ó»¡ Âùª¼¸ÕÅç À³¬O¨ü¸ÕªÌ»PÂå®vÅ@¤h¬Ò¤£ª¾¦ó¤H¦b¦ó²Õ ¦ýÂåÅ@¤Hû¥i®Ú¾Ú°Æ§@¥Îªº±¡ªp §PÂ_¥X¨ü¸ÕªÌ¬O¥Î¦óºØÃľ¯ ¬O¤p§Ìªº²q·Q ¤£ª¾¤j®a¦³¨Sª`·N¨ì ¯E¹©OBI-822Á{§Éªº¸ê®Æ ©Û¦¬¨ü¸ÕªÌªº¥Dn¯Ç¤J±ø¥ó3. ¡§µL½×HER2¡A»Û¿E¯À¨üÅé©Î¶ÀÅé¿E¯À¨üÅ骺ÀËÅçµ²ªG¬O¶§©Ê©Î³±©Ê¡A¬Ò¥i¶i¤J¥»¸ÕÅç¡C¡K ¡§ ²{¤µ§@¬°¥Dnµû¦ôªvÀøªº«ü¼Ð HER2 »Û¿E¯À¨üÅé©Î¶ÀÅé¿E¯À¨üÅé µL½×¶§³±©Ê¬Ò¥i ³o¼Ëªº±ø¥ó ´X¥G²[¬A©Ò¦³¨ÅÀù±wªÌ³£¥i¥H°Ñ¥[¸ÕÅç ¬°¦ó¤£¬O¥HGlobo H ªº¶§³±©Ê¬°¸ÕÅ窺°ò¦ ¬D¿ï¶§©ÊªÌ°Ñ»P ³o¼Ë¤£¬O§ó¯à¥YÅãÃĮĶÜ?! ¦p¦¹«K¥i¦b¡¨ ´Á¤¤¤ÀªR ¡§®É ´N¯à¦]ÃĮĬð¥X ¹F¨ì²Îp¾Ç¤Wªº©úÅã®t²§ ¦ÓÁYµu¸ÕÅç®Éµ{ ¦¤é¥Ó½Ð¤W¥« ³o¥i¯à¬O¤p§Ì¯Ê¥F±M·~ªº·Qªk Á{§É¸ÕÅç¬O°ª«×±M·~ªº²£ª« ³]p¤£¨}ªÖ©w¼vÅT¸ÕÅ窺²Îpµ²ªG ¤½¥q¥H¨ä°ª«×±M·~©M¦¨¥\ªº¸gÅç §Ú̬۫H³o¼Ë³]pÀ³¦³¨ä±M·~ªº¦Ò¶q ¥²µM¬O³Ì¨Îªº ÁÂÁ¤j®a! |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2013/4/28 ¤U¤È 10:20:58²Ä 67 ½g¦^À³
|
ÁÂÁ²q·Q¤jªº¦^µª¡C §Ú¦³§ä¨ì¤@Ó¨ÅÀù±wªÌªº³¡¸¨®æ,¸Ì±¦³¥|¤Q´X¦ì±wªÌ,¦³¨Ç¤]¦³¤½¶}e-mail, ¦ý°ò¥»¤W¨C¦ì³£¦³³¡¸¨®æ,¥i¥H¯d¨¥¡C §Ú¤£ª¾¹D¦pªG¶K¤WOBI-822ªº¸ê°Tºâ¬O¤@ºØÄÌÂZ©Î¬O¤@ºØÀ°§U? ¤]³\¦o̦´N³£ª¾¹D³oÓ°T®§¤F¡C ¥t¥~¦pªG¦o̪¾¹D§Úªº¥Dn¥Øªº¬O¬°¤FªÑ²¼¤£ª¾°µ¦ó·P·Q? «á¨Ó,§Ú¥u¿ï¾Ü¨ä¤¤¤@¦ì°Ý°Ý¬Ý,¦pªG½ð¨ìÅKªO´N§@½}... ¦pªG¯à°Ý¨ì¤@¨Çµïµ·°¨¸ñ,³oÓºâ¬O²Ä¤@¤âªº¸ê°T,«D±`Ä_¶Q,¦³°Ý¨ì¦A¦Ò¼{¬O§_¦b¦¹PO¤W¤À¨É¤j®a¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/4/28 ¤U¤È 09:52:49²Ä 66 ½g¦^À³
|
£~£~¤j ¤p§Ì¤]¬O§ä¤£¨ì§r! ¤£µM¤£·|»¡ ªÑªF·|®É«Øij±i¸³¤½§i ¤p§Ì¬O³o¼Ë§PÂ_ªº ¬JµM¥i¥H¶i¤JÁ{§É¤T´Á ·Q¥²¤G´Áªº¼Æ¾Ú¤]À³¦b¤ô·Ç¤§¤W ¦]¬°¨ü¸ÕªÌ±µ¨üªvÀøªº®É¶¡Á٫ܵu ¥Ø«e¥i¯à¥u¥i¤ñ¸û¥X¸ÕÅç²Õ»P¹ï·Ó²Õ ¦bPFSªº²Îpµ²ªG OS¥i¯à¤´Ä~ÄòÆ[¹î²Îp¤¤ ¥H¤U¬O¤p§ÌÂà¸ü¦Û ¡i¥xÆWÃÄ«~Á{§É¸ÕÅç¸ê°Tºô¡j ½Ð¤j®a°Ñ¦Ò ¸ÕÅçp¹º¦WºÙ¡G ÀH¾÷¤À°t¡BÂùª¼¡B²Ä¤G´Á/²Ä¤T´ÁÁ{§É¸ÕÅç¡A¥HGlobo H-KLH (OPT-822) ¥D°Ê§K¬ÌÀøªkªvÀøÂಾ©Ê¤§¨ÅÀù±wªÌ¡C ¡@ ¸ÕÅç¥Ó½ÐªÌ¡G ¥C¥H«ä¥Í§ÞÅU°Ý¦³¤½¥q ¸ÕÅç©e°U/ÃÙ§U³æ¦ì¦WºÙ¡G ¥xÆW¯E¹©¥Í§ÞªÑ¥÷¦³¤½¥q ¸ÕÅçp¹º®Ñ½s¸¹¡G OPT-822-001 ®Öã°õ¦æ¤å¸¹¡G 0991412420 µn¿ý¤é´Á¡G 2010-10-07 ¸ÕÅç¹wp°õ¦æ´Á¶¡¡G 2010-08-01 ¦Ü 2014-02-28 ¸ÕÅç¥Øªº µû¦ôÂಾ©Ê¤§¨ÅÀù±wªÌ¦b¦X¨Ö¨Ï¥Î¸ÕÅçÃĪ«OPT-822/OPT-821¥[¤Wcyclophosphamide¹ï©ó©µªøµL¯e¯f¶i®i¦s¬¡´Á (progression free survival, PFS)ªº§@¥Î¬O§_Àu©ó¹ï·Ó²Õ¥[¤Wcyclophosphamide¡C ¸ÕÅ綥¬q¤À¯Å Phase ¢º,Phase ¢» ÃÄ«~¦WºÙ OPT821/OPT822 ¥D¦¨¤À,¾¯«¬,¾¯¶q Globo-H-KLH QS-21,vial,250£gg/ml 75£gg/ml «ÅºÙ¾AÀ³¯g ¨ÅÀù ¸ÕÅçÂå°| / ¨ü¸ÕªÌ ¥l¶Òª¬ºA ¸ÕÅçÂå°| ¨ü¸ÕªÌ¥l¶Òª¬ºA ¤TxÁ`Âå°|ªþ³]¥Á²³¶EÀøªA°È³B 2011-02-22 ¥l¶Ò¤¤ ¤¤°êÂåÃĤj¾Çªþ³]Âå°| 2011-02-23 ¥l¶Ò¤¤ ¦æ¬F°|°êx°h°£§Ð©x§L»²¾É©eû·|¥x¤¤ºa¥ÁÁ`Âå°| 2011-02-11 ¥l¶Ò¤¤ ¦æ¬F°|°êx°h°£§Ð©x§L»²¾É©eû·|¥x¥_ºa¥ÁÁ`Âå°| 2011-04-21 ¥l¶Ò¤¤ ¦æ¬F°|°êx°h°£§Ð©x§L»²¾É©eû·|°ª¶¯ºa¥ÁÁ`Âå°| 2011-02-22 ¥l¶Ò¤¤ ¦æ¬F°|½Ã¥Í¸pÂù©MÂå°| N/A N/A °]¹Îªk¤H¨p¥ß°ª¶¯Âå¾Ç¤j¾Çªþ³]¤¤©M¬ö©ÀÂå°| 2010-12-20 ¥l¶Ò¤¤ °]¹Îªk¤H©_¬üÂå°| 2011-01-19 ¥l¶Ò¤¤ °]¹Îªk¤Hªø©°¬ö©ÀÂå°|¤Î¨äªL¤f¤À°|¤Î¨äªL¤f¨àµ£¤À°| 2010-12-17 ¥l¶Ò¤¤ °]¹Îªk¤Hªø©°¬ö©ÀÂå°|°ª¶¯¤À°| 2011-03-03 ¥l¶Ò¤¤ °]¹Îªk¤H¶d¤½«G°òª÷·|©M«HªvÀù¤¤¤ßÂå°| N/A ©|¥¼¶}©l °]¹Îªk¤H¹ü¤Æ°ò·þ±ÐÂå°| 2010-12-07 ¥l¶Ò¤¤ °]¹Îªk¤H»OÆW°ò·þªø¦Ñ±Ð·|°¨°º¬ö©ÀªÀ·|¨Æ·~°òª÷·|°¨°º¬ö©ÀÂå°|¤Î¨ä²H¤ô¤À°| 2011-01-18 ¥l¶Ò¤¤ °ê¥ß¦¨¥\¤j¾ÇÂå¾Ç°|ªþ³]Âå°| 2010-12-29 ¥l¶Ò¤¤ °ê¥ß»OÆW¤j¾ÇÂå¾Ç°|ªþ³]Âå°| 2010-12-02 ¥l¶Ò¤¤ µû¦ô«ü¼Ð(endpoint) 1. ¥Dnµû¦ô«ü¼Ð¡G ƒÜ µL¯e¯f¶i®i¦s¬¡´Á (progression free survival, PFS) 2. ¦¸nµû¦ô«ü¼Ð¡G ƒÜ Á`¦s¬¡´Á (overall survival, OS)- ©Ò¦³¨ü¸ÕªÌ±N·|³Q°lÂܤ¦~ ƒÜ Åé²G©Ê§K¬Ì¤ÏÀ³(µû¦ôGlobo H ªºIgG¥H¤ÎIgM§K¬Ì¤ÏÀ³)¡C ƒÜ ¦w¥þµû¦ô- ¤£¨}¤ÏÀ³¡A¨Ö¥ÎÃÄ¡A¹êÅç«ÇÀˬd¡A¥Í©R¼x¶H¥H¤Î¤ß¹q¹Ï ¥Dn¯Ç¤J/±Æ°£±ø¥ó *¥Dn¯Ç¤J±ø¥ó¡G 1. 2. ±wªÌ¶·¬°Âಾ©Ê¨ÅÀù±wªÌ¥B¦b±µ¨ü¦Ü¤Ö¤@½uªº¤ÆÀøÃĪ««á¹F¨ì§¹¥þ½w¸Ñ¡A³¡¤À½w¸Ñ¡A©Î¯e¯féwªºª¬ºA¡C 2. ±wªÌ¦]¤§«eªºªvÀø©Ò²£¥Í¤§¬r©Ê¶·¤w½w¸Ñ¡C 3. µL½×HER2¡A»Û¿E¯À¨üÅé©Î¶ÀÅé¿E¯À¨üÅ骺ÀËÅçµ²ªG¬O¶§©Ê©Î³±©Ê¡A¬Ò¥i¶i¤J¥»¸ÕÅç¡CµM¦Ó¡AHER2ÀËÅ笰¶§©Ê¥B¹ïHerceptin¦³¨}¦n¤ÏÀ³ªº±wªÌ¡A¨ÃÄ~Äò¨Ï¥ÎHerceptinªvÀøªÌ¡A´N¤£¯à¥[¤J¥»¸ÕÅç¡CµM¦Ó¡AY±wªÌ¹ï°Ñ»P¦¹¸ÕÅçªí¥Ü±j¯P·NÄ@¨ÃµL¨Ï¥ÎHerceptinªvÀøªÌ¡A©Î¬OHerceptinªvÀø¬°¦¹±wªÌ¤§¸T§ÒÃĪ«¡A¡]¨Ò¦p¡G±wªÌ¥»¨¤w¦³¼ç¦b¤ß¦åºÞ¯e¯f©Î¬O¦s¦bµo¥ÍHerceptin¬ÛÃö¤ß¦åºÞ¬r©Êªº·ÀI¡^§Y¥i¯Ç¤J¥»¸ÕÅç¡C ¡K¡K.µ¥ *¥Dn±Æ°£±ø¥ó¡G 1. ±wªÌªA¥Î¨ä¥L§ÜÀùÃĪ«¡A¦ýÂùÁC»ÄÆQÃĪ«©M²üº¸»XÀøªk¤£¦b¦¹¡]¦b¸ÕÅç´Á¶¡¡A¨Ï¥Î²üº¸»XÀøªkªº±wªÌ¡AÀ³ºû«ù©T©w¾¯¶q¥B¤£À³§ó§ï¥Ø«eªºÀøµ{¡^¡C 2. ¶Èµo¥Í°©Âಾ¥B¨S¦³¨ä¥L¤ºÅ¦Âಾ©Î³n²Õ´Âಾ¯f¥vªº±wªÌ¡C 3. ¦³¤¤¼Ï¯«¸gÂಾÃҾکίf¥vªº±wªÌ¡C 4. ¦b¶i¤J¸ÕÅç«e¤¦~¤º¦³¨ä¥LÀù¯g¯f¥vªº±wªÌ¡]°ò©³²ÓM¥Ö½§Àù©M¤l®cÀVì¦ìÀù¤£¦b¦¹¡^¡C 5. ¦³±µ¨üµÊŦ¤Á°£¤â³Nªº±wªÌ¡C 6. ±w¦³¤HÃþ§K¬Ì¤£¥þ¯f¬r¡]HIV¡^·P¬Vªº±wªÌ¡C 7. ±w¦³¥ô¦ó«¤j¦ÛÅé§K¬Ì©Ê¯e¯fªº±wªÌ¡]¨Ò¦p¡G²Ä¤@«¬¥®¦~«¬¿}§¿¯f¡AÃþ·Àã©ÊÃö¸`ª¢§ÜÅ鶧©Ê¡A¸¯·ç¤Ò¯÷¯f¡A¯T½H¡Aµw¥Ö¯g¡A¨t²Î©Ê¦åºÞª¢¡A·»¦å©Ê³h¦å¡A§K¬Ì´C¤¶©Ê¦å¤pªO´î¤Ö¡A¾ô¥»¤ó¥Òª¬¸¢ª¢¡^©Î¬O»Ýn¨t²Î©Êµ¹¤©Ãþ©T¾J¡]¤fªA©Î¬OÀR¯ßª`®g¡^¡A¥H¤Î»Ýn§K¬Ì§í¨î©Î§K¬Ì½Õ¸`ÀøªkªvÀøªº±wªÌ¡C¦ý±w¦³¥Ö½§ªº¦ÛÅé§K¬Ì¯e¯fªº±wªÌ¤£¦b¦¹¡]¨Ò¦p¡G°®Å~¡^¡A¦b¦¹ª¬ªp¤U¡A¥~¥ÎÃþ©T¾J¬O¥i¥H¤¹³\ªº¡C 8.±wªÌ±w¦³¤wª¾±±¨î¤£¨}ªº¨Öµo¯g¡A¥]¬A²{¦sªº·P¬V¡A¤w¦³¯gª¬ªº¥R¦å©Ê¤ßŦ°IºÜ¡A¤£Ã©w©Ê¤ßµ±µh¡A ¤ß«ß¤£¾ã¡Aºë¯«¯e¯f¡A©Î·|¨î±wªÌ¹ï©ó¸ÕÅ窺¨Ì±q©ÊªºªÀ¥æÀô¹Ò¡C ¡K¡K.µ¥ ¸ÕÅçpµeÁpµ¸¸ê°T ¸ÕÅçpµeÁpµ¸¤H©m¦W¹q¸Ü¡G³¯iÞ³ (02)2655-8799 ¸ÕÅçpµe¨ü¸ÕªÌ¦¬¯Ç¤H¼Æ ¥»pµe¹wp¦¬¯Ç¨ü¸ÕªÌ¤H¼Æ¡G¥xÆW¤H¼Æ 180 ¤H¡A¥þ²y¤H¼Æ 342 ¤H |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2013/4/28 ¤U¤È 05:54:36²Ä 65 ½g¦^À³
|
²q¤j! ½Ð°ÝTFDA¤G´Áªº¸ÕÅçµ²ªGn¦b¨º¸Ì¬d? §Ú¹M´M¤£µÛ°Ú! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/4/28 ¤U¤È 04:24:05²Ä 64 ½g¦^À³
|
«Ó¤j ±z¦í¥x¥_¯u¦n Å¥ºtÁ¿ ¾Ç²ß·sª¾ÃÑ §l¦¬·sÆ[©À ¦h¤è«K YÀY¤j¤jªº±M·~«ü¤Þ Åý¤p§Ì¦n¥Í¸r¼} ±M·~°£¤F¥»·~¥iµo´§ ÁÙ¥i®³¨Ó°µ§ë¸ê§PÂ_ YÀY¤j¤j¯uªºÁÂÁ±z ±z»¡ªº¨º½g¤å³¹ ¤p§Ì¾ãÓ°²´Á³£¦b®ø¤Æ ¦Ü¤µ¤´¬O®ø¤Æ¤£¨} Åý¤p§Ì¨C¬P´Á¤W®Ñ§½¬ÝÂø»xªº²ßºD©µ»~¤F ¬JµM«Ó¤j´£¨Ñ¦nªº³ø¾É ¤p§Ì¤U¤È¹B°Ê«á ÁÙ¬O±o¶]¤@½ë §l¦¬¤@¤U¦nªºÆ[©À «Ó¤jÁÂÁ±z! «Ó¤j»¡±o§õ¥@¤¯³Õ¤h ¬O¯E¹©¸³¨Æ---^Äݺû¨Ê¸s®q°ÓAlpha Corporateªº¥Nªí¤H ¸Ó¤½¥q«ù¦³ªñ9885±i §õ³Õ¤h»¡ªº¹w¨¾ «ê»P¤p§Ì«e¤å©Ò´£ªº²q·Q¦ü¦³¦P¤u¤§§® ¤p§Ì«e¤å¦bÁ¿zÁÞ´¹¤ù ¥Î¨ÓÅéÀË¿z¿ï¯e¯f®É Y¬Y¤H¸gÀËÅ禳Globo H ¶§©Ê ´Nªí¥Ü¦³¨º8ºØÀù¯gªº¥i¯à ¨º«ç»ò¿ì ´N¬O¨Ï¥ÎOBI-822©Î833 ¨Ó²M°£³o¨ÇÁ٫ܤp ®ÖÂå©|Àˤ£¥Xªº¯f·½ ¦]¬°¥¦Ì°Æ§@¥Î¤p ¦w¥þ¤S¦³±M¤@©Ê ¥BYÀY¤j¤j«ü¤Þ¤p§Ì¬Ýªº¤å³¹¤¤ ¤]´£¤Î ³oÃþ¬Ì]¥i¯à¹ï¸~½F©|¤p®É³Ì¦³Àø®Ä(À³¬O§@ªÌ®Ú¾Ú±M·~ªº§PÂ_) Bill¤j ©M ´µ¯S¤j ¤]»¡±o«Üºëªö ¬Ý¤½¥qªº°Ê§@¨Ó²q·Q¤½¥q¹ï¥¼¨Óªº³W¹º Á`¸g²z´«¦¨¥H¦æ¾P¨£ªøªº±M®a ¤S¦b¦Ë¥_»\¼t½m§L Å㨣¤½¥q¹ï¦Û¤v·sÃĪº«H¤ß «e±¤p§Ì·Q½Ð¦í¦Ë¥_ªþªñªº¤j¤j «e¥hÅçÃÒ¤½¥q¦³µL¯uªº°Ê¤u»\¼t¤F ³o¬O¤p§Ì·QÅçÃÒ¤½¥q»¡ªk»P¦æ°Ê¬O§_¦³¸¨®t ¦P®É»\¼t¤]¬O³Ì«nªº«H¤ß«Å¥Ü ¤£¬O¶Ü?! »·¶¯¦ÑÁ󪺼s§iµü n¶R´N¶R³Ì¦nªº ¿Å½Ñ²{¤µª©±ªº·sÃÄªÑ ¨ºÀɬO±z¤ß¥Ø¤¤³Ì¦nªº? ¡K ½Ðì½Ì¤p§Ì·R»¡¸Üªº¤ò¯f ·sÃħë¸ê·ÀI«Ü°ª ½Ð¤j®a¿Å¶q¦Û¤v·ÀIªº@¨ü«× ¶q¤O¬°¤§ ÁÂÁ±z! ¥t¥~¤p§Ì¬Ý¨ì¤@¨Ç¤j¤j¦³©Ò°ÝÃD ¦ý¨S¤HÀ°¦£¦^µª ¤p§Ì²³æ¥Nµª Po¤j ²{ª÷¼W¸ê ¯E¹©©|¥¼°e¥ó¥Ó½Ð ¨º¤Ñ¬Ý¨ì¤F ¦A§i¶D¤j®a P§Ú¤j °ò¥»¤Wn¬d¶À¥D¥ô¦³µL«ùªÑ «ÜÃø ¤¨¦ÑÁó¥h¦~Â൹ªº¯S©w¤H ¨ÃµL¶À¥D¥ôªº¦W¦r ¥x¤jÂå°|¬O¤½¥ßÂå°| ©Î³\³W©w¤ñ¸ûÄY®æ §Y¨Ï¥L¹Î¶¤ªº¦¨û À³¤]¤£ª¾¦p¦¹¨p±Kªº¨Æ ¦P®ÉÁÂÁ±zªº¸ê°T P???¤j °ò¥»¤W©ê¤jÁ¿ªº¬O ±z¶g¤ÁÙ«ù¦³¯E¹©ªº¸Ü ´N¥i¥H°Ñ¥[6/26ªºªÑªF·| ¦Ü©ó²{¼W ÁÙ¥¼©w®× °²¦p¥H«á±z¦³°Ñ»P°£Åv(°£Åv·í¤é ±zÁÙ¦³«ùªÑ)³£¦³Åv¨Ì¤ñ²v»{ÁÊ ¦n¹³2%ªþªñ ±z¥i¥H¥h"¤½¶}¸ê°TÆ[´ú¯¸"¬d¸ß ÁÂÁ¤j®a! ½Ð¤j®a·V«ä©ú¿ë °µ¦n¦Û¤vªº·ÀI±±ºÞ |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2013/4/28 ¤U¤È 03:31:22²Ä 63 ½g¦^À³
|
³oÓªFªF¬O¨ë¿E§K¬Ì¨t²ÎªºT²ÓM¥h®ø·À8ºØÀù²ÓM, §ÚÌ°·±dªº¤H¨ä¹êÅ餺¦h¤Ö¦³¤@¨ÇÀù²ÓM, ¥u¬O§K¬Ì¨t²Î¤]·|¦Û°Ê¥h®ø·À¥¦Ì¡C ·í§Ú̪º§K¬Ì¨t²Î¨Ó¤£¤Î®ø·À¥¦Ì®É,Àù²ÓM´N¶}©l·U¨Ó·U¦h, ¨¾·L§ùº¥,±j¤Æ§K¬Ì¨t²Î²M°£³o¨ÇÀù²ÓM¬O³Ì¨Îªº¹w¨¾¤è¦¡¡C ¤@¦¸8ºØÀù¡C ¦Ó¥B,²{¦b³£¬O§ä¤wÂಾªºÀù¥½¯f¤H°µ¸ÕÅç,¦pªG¬O§ä©|¥¼Âಾªº¯f¤H, ¨º®ÄªG«Ü¥i¯à¬O100%,¨º¤£¬O¯S®ÄÃĬO¤°»ò? ¦A¨Ó´N¬O§ó·sªºªF¦è®ÄªGÁÙ§ó©úÅã,¥»¨Óªº´N¥@¬É¦a¤@¤F, ¨º»ò§ó·sªº¤£´N¥s¤@°ïÃĦ¬°_¨Ó¤F¶Ü? ¨ì®ÉÔ·|¤£·|¤@°ï¤jÃļt¤Sn¨Ï¥X¨õ»Àªº¤â¬q¦Ê¯ëªý¼¸´N«ÜÃø»¡¤F¡C ©ÎªÌ¤¤¶¡·|¤£·|¥X²{¤@¨Ç³±¿Ñ¤]«ÜÃøÁ¿¡C §Ú´Nı±o¤é¥»¤j¶ï³Qð联±ÂÅv®Ú¥»´N¬OÓ³±¿Ñ¡C ³o¬OÓ¤HªºÆ[ÂI,¤£¤@©w¥¿½T¡C |
|
|
·|û¡G¤j«Ó10135703 µoªí®É¶¡:2013/4/28 ¤U¤È 01:50:20²Ä 62 ½g¦^À³
|
¤j«Ó¶R¤F³o¤@´Áª÷¿Ä®a¤ë¥Z,µoı¥L¹ï¥Í§Þ¥Í§ÞªÑªº¼Ò¦¡¦æ¬°¤¶²Ð«Ü¸Ô²Ó,µ¹«Ü¦hªì¾ÇªÌ¤@¨Ç¤èªk¸ò«Øij,¥i¥H«Øij¹ï¥Í§Þ¦³¿³½ì§ë¸êªB¤Í¶R¨Ó¬Ý,¨ä¤¤¤j«Ó¬Ý¨ì¤@½g¤å³¹,¬O§õ¥@¤¯³Õ¤h¼gªº,¥L´£¥X¤ÓÆ[¹î«ü¼Ð1.±M§Q¼h¦¸ 2.¬O§_¬D¹ï¥«³õ 3.Á{§É¸ÕÅç¬O§_±o¥H¶i¦æ 4.ÃÄ«~¬O§_¤Íµ½ 5.Ävª§µ¦²¤ ¨ä¤¤¦n´X¶µ¸ò«Ó¤j²z©À¤@P,Ä´¦p¥«³õ,Á|¨xÀù¦n¤F,¨È¬w¤¤°ê¤ñ«¶W¹L¤¦¨,¬ü°ê«o¥u¦³2%,¦pªGn±ÂÅv,¦ÛµM¿³½ì¯Ê¯Ê(°ò¨È) ¦A¨ÓÃÄ«~·Å©MµL°Æ§@¥Î,¬I¥´¤è«K.¦A¨ÓÄvª§µ¦²¤:¥xÆW·sÃĤ½¥q´X¥G¨S¦³¦Û¤v¾P°â³q¸ô,¤Î«K·sÃĦ¨¥\¤W¥«,¤]»Ýn³z¹L±ÂÅv°ê»ÚÃļt¶i¦æ¾P°â,(´¼Àº) ¤Wz¨Ó»¡¥H¯E¹©§¹¥þâ¾r°ò¨È´¼Àº¤§¤W ¬Ý¦n¥xÆW¯E¹©¬D¾Ô¨ÅÀù·sÃIJz¥Ñ:¥Ø«e¥«³õ¤Wù¤ó¶PÀù¥,1y½æ60e¬üª÷¾A¥Î25%¯f¤H,¯E¹©ÃĪ«90%¯f¤H¥i¥H¨Ï¥Î(¾÷²v¤S´£°ª¤F¬O³Õ¤h»¡ªº)¥«³õ¹F¶PÀù¥3-4¿(´«¥y¸Ü»¡¤j©ó200e¬üª÷),¤]µo²{8ºØ¯f¤H¦P¼Ë±a¦³globo h§Üì,¬Æ¦Ü·í§@¹w¨¾³£¥i¥H(ª`·N³o¥y¸Ü,¹w¨¾?¨º¥Nªí¦pªG·sÃįuªº¦¨¥\,°·±dªº¤H¤]¥i¬I¥´?·í§@¹w¨¾Àù¯g?¤Ñªü,¨º°Ó¾÷????¦pªG¦³¤@´ÚÃÄ,¥´¹w¨¾¥i¥H¤£·|±o¯f©Î¬O°§C¿©±w¾÷²v?«¢¨º§ÚµLªk·Q¹³,¦³³oºØ¸ó¥@¥NÃĪ«²£¥Í),±µµÛ¥L»¡¨ÅÀù¬O¥þ²y¤jÃÄ,¦¨¥\»P§_¥þ²y³£¦b¬Ý,¤@¥¹³q¹L¦b°ê¥~³£¬O«Ü¤j²£«~,¦b¬ü°ê³£·|¬O¤j·s»D ¤À¨É³o½gµ¹¤j®a^^,¤¤ë¥÷ª÷¿Ä®a¥Í§ÞÁ¿®y5/4¸ò5/9¸¹ªº½ÒºtÁ¿,«Ó¤j¦³¥i¯à·|¥hÅ¥¤@Å¥,¦³¿³½ìªB¤Í¤]¥i¥H¤@°_¥h |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2013/4/27 ¤U¤È 11:01:42²Ä 61 ½g¦^À³
|
§Ú¥uª¾¹D:¤@´Á41%¶W¹L¤Q¦~¦s¬¡,78%¶W¹L¥|¦~¦s¬¡¡C (¨ÅÀù±wªÌµo¥ÍÂಾ«á¡A§Y¨Ï¦A±µ¨üªvÀø¡A¥§¡¥u¯à¦s¬¡2¨ì3¦~¡A5¦~¦s¬¡²v¤£¨ì¤G¦¨¡C) ½Ð°ÝTFDA¤G´Áªº¸ÕÅçµ²ªGn¦b¨º¸Ì¬d? ¤T´Á²{¦b¤E°w¤j¦h¥´¹L¤F§a?¦bµ¥¨â¦~¬Ýµ²ªG¶Ü?¦pªG¬O³o¼Ë,¨ºªí¥Ü®ÄªG¬Û·í¥¿± |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2013/4/27 ¤U¤È 12:45:57²Ä 60 ½g¦^À³
|
¤G¦ì³o»ò¤@»¡,¤p§Ì©ú¤Ñ´N¶}©l±j¤O¶R¶i¤F! ·Ç³Æ©Ð¦a¥Ð²£¦Ñ±C¥þ½æ¥ú,©tª`¤@ÂY¤F! |
|
|
·|û¡Gªü¤Ñ10135877 µoªí®É¶¡:2013/4/27 ¤W¤È 09:30:09²Ä 59 ½g¦^À³
|
½Ð°Ý´µ¯S¤j¬°¦ó¤£¤ñ¸ûPhase II,§Ú°O±o¦³300¦h¯f±w¦bPhase IIªº®ÄªG¥ç¨ôµÛ |
|
|
·|û¡G´µ¯S10135783 µoªí®É¶¡:2013/4/26 ¤U¤È 11:14:25²Ä 58 ½g¦^À³
|
»OÆW¥Ø«e¶i¦æphase III study,¦³15®aÂå°|¥[¤J,Phase III¬OÂùª¼ study,¤@²Õ¥´ÃÄ,¤@²Õ¥´ªº¨S¦³ÃÄ(placebo¦w¼¢¾¯),¦]¬°OBI821 side effect ¤p,©Ò¥H¯f¤H°Ñ¥[·NÄ@·|¸û°ª,¦ÛµM¶i«×·|¶W«e,°Ñ¥[study¯f¤H¤ÎÂå®v¬Ò¤£ª¾¨º¦ì¯f¤H¬O¥´ÃÄ,¨º¦ì¯f¤H¬O¤£¥´ÃÄ,¦A¥[¤W§K¬ÌÀøªk¤ÏÀ³ºC,©Ò¥HPhase III ªºµ²ªG¨S¨º»ò§Ö¥X¨Ó,¦pªG¯u¦pphase I date¼Æ¾Ú¦bphase III ¤W,¨ºµ´¹ï¬O°ê»Ú¯ÅÃĪ«,¥²ºÉ«Ü¦hFDA³q¹Lªº¤ÆÀøÃÄ,¦³¨Ç¥u¯à©µªø2-3Ó¤ë,¨C¤ë¶O¥Î°ª¹F10-20¸U¥x¹ô.¬Û«Hphase I = phase IIIªº¤H´N¥[½X©Îªø´Á§ë¸ê,¤£¬Û«Hphase I = phase IIIªº¤H,À³¸Ó¥ß§Y±þ¥X,·sÃĬãµo,¤£¦¨¥\Åܦ¨¤¯.µ¥¨ì¦~©³ phase III µ²ªG¦p³°Äò¶Ç¥X¦nµ²ªG,´N¤£¬O200¥H¤U.¥Lªº»ùȱN¶W©¿·Q¹³. |
|
|
·|û¡Gharrison_c10136250 µoªí®É¶¡:2013/4/26 ¤U¤È 04:43:40²Ä 57 ½g¦^À³
|
©ê¤j, Å¥¨¿´f·Oªº¨º·|µo¤j°],¨º´N¦Û¤v¤£¥Î§@¤ÀªR®v¤F ¡CªÑ²¼n½æ±¼¤F¤~¯àºâ¯uªºÁÈ¿ú.¥Í§ÞªÑªº·ÀI«D±`°ª. |
|
|
·|û¡Gbill10135881 µoªí®É¶¡:2013/4/26 ¤U¤È 04:10:42²Ä 56 ½g¦^À³
|
¯E¹©¦³ªÑ¤ý¬Û §Ú·Q¥»ª©ªø§ë¤j¤j̳£·|»¡¡y»á¦³¦P·P¡z ¦~ªì´N§â¤¤¸Î½Õ¸`¤@¥bÂà¶i¯E¹© ¨âªÌ³£¬O¤¨¦ÑªOªº¥Í§ÞªÑ ³£¬O¤W¤W¤§¿ï!!~ |
|
|
·|û¡G¦º©ê10136078 µoªí®É¶¡:2013/4/26 ¤U¤È 03:42:33²Ä 55 ½g¦^À³
|
???¤j: «Ü©êºpµLªk¦^µª±zªº°ÝÃD ¦]¬°§Ú¥u¬O¤@Ó§â©Ò¦³¸êª÷¥þ©ã¯E¹©ªº¤p´²¤á ¥L¬O¥Ø«eÅý§ÚÁȳ̦h¿úªºªÑ²¼ §â§Ú¥H«e¿éªº¥þŦ^¨Ó ¦Ó¥B§Ú³ßÅw¥Lªº¦W¦r ¦³ªÑ¤ý¬Û ¨¿¿··O¤ÀªR®v¤]´¿»¡¥L¬O·~¬É¤½»{¥¼¨Óªº¥Í§ÞªÑ¤ý |
|
|
·|û¡Gharrison_c10136250 µoªí®É¶¡:2013/4/26 ¤U¤È 02:02:36²Ä 54 ½g¦^À³
|
³s²{¼W³£ÁÙ¨S°e¥DºÞ¾÷Ãö,°ò·Ç¤é³£ÁÙ¨S©w. |
|
|
·|û¡G???10135085 µoªí®É¶¡:2013/4/26 ¤U¤È 01:51:54²Ä 53 ½g¦^À³
|
½Ð°Ý©ê¤j: ¬O¤£¬O¤µ¤Ñ¦¬½L«á§Ú¤â¤W¦³¯E¹©ªºªÑ²¼§Ú´N¥i¥H°Ñ¥[²{¼W©O?Y§Ú¦³5±i§Ú¥i¥H»{Áʦh¤Ö? |
|
|
·|û¡Gharrison_c10136250 µoªí®É¶¡:2013/4/26 ¤U¤È 01:48:41²Ä 52 ½g¦^À³
|
¥Í§ÞªÑ±q¤G¤ë¥H¨Ó¾_Àúªº¦n¼@¯P¼Ú.ÀY³£§Ö³Q¾_©ü¤F. |
|
|
·|û¡Gbill10135881 µoªí®É¶¡:2013/4/26 ¤U¤È 01:29:10²Ä 51 ½g¦^À³
|
¦U¥ý¶i¤j¤jªº±M·~ª¾ÃÑÅý¤H§éªA¡A Á{§Éµ²ªG¨ã¦³²`«×¡A«D¤½¥q¤º³¡¤H«ÜÃø´£«eª¾¹D§G§½§ë¸ê¡A ¦ý¦pªG¯à±q¤½¥q¤w³zÅS¥Xªº¤è¦V¡A¤]¥iÂk¯Ç¥X¤@¨Ç¨Ç½ü¹ø¡A ¦pªñ´Á¤¨¦ÑªOµÛ¤ân¦b¦Ë¥_¥ÍÂå¶é°Ï»\¤@®y¡y¥@¬É¯Åªº³J¥Õ½èÃļt¡z ¦Ó³o¦¸¤¨¦ÑªO¥D¾É»\¼tªº¿n·¥©Ê¨Ó¬Ý À³¸Ó¥i¥H±À½×¨ì¯E¹©Á{§É¤G¤T´Áµ²ªGªº¤@¨Ç¨Ç¥i¯à¡y¯u¬Û¡z! |
|
|
·|û¡G£«ÀY10135462 µoªí®É¶¡:2013/4/26 ¤U¤È 12:56:53²Ä 50 ½g¦^À³
|
¦^µª²q·Q¤j §Úı±o§Aºâ¬O¤@ӥΥ\§ë¸êªÌ¡A¤w¸g«Ü§V¤Oªº§ä´M½u¯Á¡A¥u¬OÁ{§É¬ã¨sµ²ªG¨ã¦³¬Û·íªº²`«×¡A¤£¬O±q·~ªÌ¡AÃø¥H¬Ý¨ì¯u¬Û¡A¦h¥b±oÅ¥¤½¥qªº¡A¦¹¥~µ¥¤½¥q«Å§G¡A¤S¦³«Ü¦h½ÆÂø±n¦Ò¶q¡A©¹©¹»~¤F®É¾÷¡A°¾¤F¯u¬Û¡A³oÓ¥¼¤W¥«¥¥x¡A«Ü®e©ö³Q¥Î¨Óª£§Ë¡C §A°Ýªº°ÝÃD¡A§Ú«Øij§A¦A¬Ý¤@½g Clinical Cancer Research 2003 August 15 Vol.9 Page 3222-3234 Review ¸Ì±¦³¤@¨Çµª®×¡A¦ý¤]¥u¬O³¡¤À¡C ¤H¤H³£¦³µo¨¥ªº¦Û¥Ñ¡AÅ¥¨ìªº¸Ü½Ð¤p¤ß¨DÃÒ¡A¦n¹³¤j®a³£¾ÌµÛ·Pı¶R¥¼¤W¥«¸ò¿³ÂdªºªÑ²¼¡A¸òµÛ°Q½×ª©¤Wªº¦Ñ®v¶R¡A¥x·LÅé¤~è¤W¥«¡A¤£´N¬O¤@ӫܦnªº¨Ò¤l¶Ü¡H¤@¸ô±q¢²¢·¢¯¶^¨ì¢±¢µ¢¯¡A§A·Q·QI«á¦º¦h¤Ö¤H¡A·íµM¤]¦³¥i¯à¦³¤HÁȨì¡C ¤£¤Ó¯à°Ñ»Pµû½×¥ô¦ó¤@®a¡A³oÓ°é¤l«Ü¤p¡A«ç»ò°Â³£¦³»{ÃѪº¤H¡A§Ú¦³¨S¦³¶R½æ¹L¥¼¤W¥«©Î¿³ÂdªÑ¡A§Ú¦³ªº³£¬O¤½¥q°tªº©M¦Û¤v¬Oû¤u®É¶Rªº¡C |
|
|
·|û¡Gharrison_c10136250 µoªí®É¶¡:2013/4/26 ¤U¤È 12:42:05²Ä 49 ½g¦^À³
|
¥Í§Þn²{¼WªºªÑ²¼¦n¹³³£Åܦ¨¤F²¼©Ð¬rÃÄ.ªÑ»ù³£¬O©¹¤U¤Ï¬M. |
|
|
·|û¡G§Ú´N¬O§Ú10021927 µoªí®É¶¡:2013/4/26 ¤U¤È 12:25:22²Ä 48 ½g¦^À³
|
²q·Q¤j:ÁÂÁ±z´£¨Ñªº¬Ýªk¡C ³o¬O¨â¦~«eªº¤@½g³ø¾É,Y¦A¥[¤W³Ìªñ©Ò»¡ªº¡u¶i®i¤£¿ù¡v¡u¶i«×¶W«e¡v,¨º»ò,²q·Q¤j,±z¤£¥²¥h°Ý¶À«T¤É¤°»ò, ±z¥u»Ýn¬d¥X¥L«ù¦³´X±i´N¦n¤F¡C±z¯à¬d¨ì¶Ü?§i¶D§Ú§a? 2010.12.15 08:50 pm...¡u¥x¤jÂå°|¨Å©ÐÂå¾Ç¤¤¤ß¥D¥ô¶À«T¤É«ü¥X¡A¥þ²y²Ä¤@Өũи~½FªvÀø¬Ì]±N¶i¤J¶i2¡B3´ÁÁ{§É¸ÕÅç¡A¨Ã¥Ñ¥xÆW¥D¾É¤Ó¥¬v¦è©¤4°ê¸ó¤¤¤ßªº¬ã¨s¡A¤@¥¹ÃÒ¹êÀø®ÄÅãµÛ¡A§Y¨Ï¤wÂಾªº¨ÅÀù¯f±w¤´¦³ªñ8¦¨¥i¦s¬¡¶W¹L4¦~¡C¡v ¥H¤W³o½gªºÁ¿ªk¡u8¦¨¡v¡u4¦~¡vÀ³¸Ó¬O³Ì«O¦uªºÁ¿ªk¡C |
|
|
·|û¡G¦º©ê10136078 µoªí®É¶¡:2013/4/26 ¤W¤È 11:51:26²Ä 47 ½g¦^À³
|
°ò¨È¬Q¤Ñ¤½§i160²{ª÷¼W¸ê |
|
|
·|û¡GµL¦W10031736 µoªí®É¶¡:2013/4/26 ¤W¤È 11:28:00²Ä 46 ½g¦^À³
|
¬Û¹ï§Ü¶^¡A·Ç³Æ¤W¡H |
|
|
·|û¡G¦º©ê10136078 µoªí®É¶¡:2013/4/26 ¤W¤È 11:07:10²Ä 45 ½g¦^À³
|
¤µ¤Ñ¤U¶^ ¤j·§¬O³Q°ò¨È©ì²Ö.. |
|
|
·|û¡Go10135877 µoªí®É¶¡:2013/4/26 ¤W¤È 10:44:12²Ä 44 ½g¦^À³
|
¤£ª¾²{ª÷¼W¸êªº°£Åv°ò¥»¤é¤½§G¤F¨S? |
|
|
·|û¡G¦º©ê10136078 µoªí®É¶¡:2013/4/26 ¤W¤È 10:26:43²Ä 43 ½g¦^À³
|
¤µ¤Ñ¬O°±¤î¹L¤á«e³Ì«á¤@Ó¥æ©ö¤é ¦½L®¼¾_Àúªº... |
|
|
·|û¡GµL¦W10031736 µoªí®É¶¡:2013/4/26 ¤W¤È 09:48:55²Ä 42 ½g¦^À³
|
¥¼¤W¥«ªÑ©ö¾Þ§Ë¡A»ù¦ì°Ñ¦Ò°Ñ¦Ò¡H¡I |
|
|
·|û¡G©P¥þ¤¯10133557 µoªí®É¶¡:2013/4/26 ¤W¤È 09:34:06²Ä 41 ½g¦^À³
|
¤Ó´ºªº½T«Ü¸Ø±i,¤j®a¯uªºn¤p¤ß,¦h°µ¥\½Ò,½Ð°Ý£«ÀY¤j¹ï¯E¹©,ÃĵØ,¤Ó´º¤TÀɪº¥¼¨Óµo®i©Ê½Í½Í±zªºÆ[ÂI |
|
|
·|û¡G¦º©ê10136078 µoªí®É¶¡:2013/4/26 ¤W¤È 09:09:34²Ä 40 ½g¦^À³
|
178¥[½X7±i |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/4/26 ¤W¤È 08:54:06²Ä 39 ½g¦^À³
|
·PÁ¤j®a¼ö¯P°Q½× ¦b¦¹ÁÂÁ¦U¦ìªºÄ_¶Q·N¨£ §ó·PÁÂYÀY¤j¤j±M·~ªºµû½× YÀY¤j¤j Á¿zªº³£¬O¤@¯ë¨Æ¹ê Á{§É¸ÕÅç·íµMµ´¤j³¡¤À¼µ¤£¨ì³Ì«á §_«h·sÃĤ£´Nº¡¤Ñ¸¤F ¦ýÓ§O·sÃĪºÁ{§É¼Æ¾Ú´Nn¥J²ÓºÝ¸Ô ³o´N¬O§Ú̧ë¸êªÌn°µªº¥\½Ò ³Ó¥Xªº¾÷·|¤~·|°ª ¤p§Ì¦b¦¹·PÁ±zµ½·Nªº´£¿ô ¤£¹L¦b¦¹ ¤p§Ì·Qn½Ð°Ý YÀY¤j¤j±z¬O§_¬Ý¹LPNAS ¨º½g¼ÐÃD¬°¡¨ Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: A phase I trial ¡§ªºOPT-822Á{§É¤@´Á³ø§i ¬O§_¯à¤À¨É±z±M·~¬Ýªk ¤p§Ì«Ü¬O´Á«Ý ³o½g2001.3.13¥Xª©ªº³ø§i À³¸Ó¬O¦b§¹¦¨Àøµ{2~¢²¦~«á©Òµoªíªº ¦b³ø§iªº¡¨ Discussion¡¨Äæ ¼g¹D¡¨ First, the most common toxicities were transient local skin reactions at the vaccine site and mild flu-like symptoms.¡K Second, vaccination of breast cancer patients with this vaccine was able to stimulate moderate IgM antibody titers in the majority of participants. ¥L¥Î¤Fmoderate ³oӧήeµü ¨Ó´yzOPT-822©Ò¤ÞµoªºIgM§ÜÅéºw«× ³ø§i¤¤ªºTable 4 ¸Ô¦C¸ÕÅçªÌ¸ÕÅç«e«áªº¬ÛÃö¼Æ¾Ú ½Ñ¦p§ÜÅéºw«× IgM§ÜÅé»PMCF-7¨ÅÀù¸~½F²ÓMªº¤ÏÀ³¦Ê¤À¤ñ ¡K µ¥ ¤p§Ì©|¦b´M§ä¨ä¶¡ªí²{»P¦s¬¡¦~¼ÆªºÃö«Y ³oÓ¸ÕÅçÂ÷²{¦b¤w¦³15~16¦~¤F §Ú̥Ѥ½¥q©Òµoªíªºªk»¡¸ê®Æ ª¾¹D¦³16 Ó¸ÕÅçªÌ¦s¬¡¶W¹L10¦~ (Æ[¹î´Á¥i¯à¬O10 ¦~) «ê²Å¦X ªvÀø«e«áIgM§ÜÅé»PMCF-7¸~½F²ÓMªº¤ÏÀ³¦Ê¤À¤ñ ¶W¹L3¿ªº±wªÌ¼Æ(´N¬O16¤H) ¦]¬°¤½¥qªk»¡·|ªº¼Æ¾Ú±wªÌ¨S¦³½s¸¹ µLªk»P³ø§i¤¤Table 4ªº±wªÌ½s¸¹®Ö¹ï ³à¥¢¶i¤@¨B¤ñ¹ïªº¾÷·| ¤p§Ì¤£ª¾¹D³o27Ó¸ÕÅçªÌ¤¤ ¦³µL¨Æ¥ýÀËÅç¬O§_¨ãGlobo H ¤Î¨ä¦b¨ÅÀù²ÓMªºªí²{¶q YµL (¤]´N¬OÀH¾÷ªº) ³oÓ¤ñ¨Ò(16/27) «ê²Å©ó¤½¥qªk»¡·|©Ò¦C¥Ü¨ÅÀù±wªÌ¤¤¨ã¦³Globo H ªº¤ñ¨Ò(6¦¨) ³o¬O¤£¬O¥i¥H±À½×¬° Y¨Æ¥ý´N¿z¿ï¨ãGlobo Hªº±wªÌ ´N¥i¥Hªñ¥G¥þ³¡¦³®Ä(³o±À½×·ÀI«Ü¤j ¤]n¬ÝGlobo H¦b¨ÅÀù²ÓMªºªí²{¶q) ¤p§Ì»{¬°³oÓ±À½×À³¸Ó¥i¥H¦¨¥ß ¬O¦]¬° ¦b±wªÌÅ餺¤Þµo°ª¿@«×§ÜÅé ¦ýY¸Ó¸ÕÅçªÌªº¸~½F²ÓMªí±¨S¦³Globo H©Îªí²{¶q§C ¦ÛµM¦a§ÜÅéµLªk§ä¨ìÀù²ÓM¤Wªº¼Ð°O(Globo H)¦Ó±N¤§ºR·´ Y¨ã ¤Îªí²{¶q°ª §Y¥iºR·´ ¦p¦¹¤@¨Ó ´N²Å¦X¤½¥qªº»¡ªk OBI-822¹ï6¦¨²¾Âà©Ê¨ÅÀù±wªÌ¦³®Ä ¤p§Ì¹Á¸Õ¹ï³o¥÷³ø§i¸ÑŪ ©Î³\¹ï±M·~ªº¤H¨Ó»¡ ¥¢¤§¥®¸X¥i¯º ³o¥÷³ø§i·íµM¤]¦s¦bµÛ¼Ë¥»¼Æ¤£¨¬ ¦Ó¦³¥H°¾·§¥þªº·ÀI ¤p§Ìª¾¹D·sÃĦæ¾P¤£©ö ²o¯A¤j¼t§Q¯q Âå®v ¤Î«OÀI¤½¥q¦h¤èªºÆ[ÂI©M±wªÌªº·Qªk ¦ý£~£~¤j»¡±o¤@°w¨£¦å ¥unÃĮİ÷¬ð¥X ´N¤£©È±wªÌ¤£±Ä¥Î ¤G´ÁÁ{§É³ø§i¬Ý6/26ªÑªF·|®É «Øij±i¸³¬O§_Ä@·N¤½¶} ¤£µM´N¬O¨ì¥x¤jÂå°|±¾¶À«T¤ÉÂå®vªºªù¶E µM«á°½°½°Ý¥L ¡§§ë¸ê¯E¹©¦³¼ç¤O¶Ü?¡¨ ¶À«T¤ÉÂå®v¬OOBI-822¦b¥xÆWÁ{§É¸ÕÅ窺Á`t³d¤H ¥t¥~¤p§Ì¦n©_ªº¬O¡¨³¡¤Àªº¨¥½×¡A¦s¦bµÛ·¥°ªªº·ÀI¡¨ ¬O§_¤]½ÐYÀY¤j¤j¤£¥Î«È®ð ª½±µ©ú¥Ü Åý¤p§Ì¦³¾Ç²ß§ï¥¿ªº¾÷·| ¥ýÁÂÁ±zªº«ü¾É! ¤]ÁÂÁ¤j®a! Án©ú: ¤p§Ìªº±M·~¥i»¡¨S¦³ ¤W¦C¬Ýªk¯Âºé¬O¤p§ÌÓ¤H«÷´ê²q·Q µLªk§@¬°±z§ë¸ê¯E¹©ªº¨Ì¾Ú ±zªº§ë¸ê«äºû©M·ÀI±±ºÞ ½Ð¨Ì±zªº¸gÅ笰¤§ ÁÂÁ±z! ¤p§Ì·Pı¦³¨Ç²Ö¤F ¤Ñ¤Ñª¦¤å¦r ¾ã¦X¸ê®Æ ®ö¶O«Ü¦h®É¶¡ ¤p§ÌÁÙ¦³«Ü¦h¸ê®Æ©|«Ý¾\Ū¬d¸ß ¥H«á¤p§Ì·|¾¨¶q´î¤Ö»¡¸Ü ¦ý¦³·sÆ[ÂI¤´·|¦V¤j®a³ø§i ¤j¤j̦³·s½×ÂIµ´¤£n¦]¤p§Ì´î¤Öµo¨¥¦Ó¥´¦í ¦³°Q½×¤~·|¶i¨B ¤~·|¼W¥[§Ú̬ݨƱ¡ªº¨¤«× ¦A¦¸ÁÂÁ¤j®a! |
|
|
·|û¡G¦º©ê10136078 µoªí®É¶¡:2013/4/26 ¤W¤È 08:30:06²Ä 38 ½g¦^À³
|
Ó¤H²L¨£¬O:¯E¹©¥Î45¤¸¤WÂd«o´±©w158¤¸¼W¸ê»ù ¤@©w¤£·|Åý§Ú̳o¨Ç¤pªÑªF¥¢±æªº... §Ú¨M©wÄ~Äò¥[½X |
|
|
·|û¡Gharrison_c10136250 µoªí®É¶¡:2013/4/26 ¤W¤È 08:11:13²Ä 37 ½g¦^À³
|
²{¦b¥Í§Þ¦n¹³¥¼¤W¥«ªº¤ñ¸û·|º¦.§C»ùªº¤]¤ñ°ª»ù¦n. |
|
|
·|û¡G¦º©ê10136078 µoªí®É¶¡:2013/4/26 ¤W¤È 08:02:22²Ä 36 ½g¦^À³
|
£~£~¤j: ±z»¡ªº¬O¤Ó´º§a! ¨ä¹êÃĵاó¸Ø±i ¥¦¥h¦~11¤ë¥Î21¤¸²{ª÷¼W¸ê ²{¤w¨Ó¨ì100¤¸¥ª¥k¤F! |
|
|
·|û¡Gharrison_c10136250 µoªí®É¶¡:2013/4/26 ¤W¤È 07:59:41²Ä 35 ½g¦^À³
|
¥Í§Þªº§ë¸ê´N¬O¤j¦n¤jÃa.ÁöµM·sÃĦ¨¥\·|±a¨Ó«Ü¤jªº¦¬¯q.¦ý¬O¦¨¥\ªº¾÷²v¸û§C.¤@¨Ç§Q°ò«¬·sÃĦ¨¥\ªº¾÷²v¸û°ª.ÁöµM¥«³õ¨S³o»ò¤j.³Ì¦nªº§@ªk´N¬O¤À´²§ë¸ê.¤è¬°¤Wµ¦. |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2013/4/25 ¤U¤È 10:02:08²Ä 34 ½g¦^À³
|
ªº½T¥Rº¡µÛ¦UºØ·ÀI,¤£¯à¥u¤@¬Nªº©¹¦nªº·Q¡C ÁÂÁ´£¿ô! §Ú©ú¤Ñ´N·|°µ¦n·ÀIºÞ±±,¥ý½æ±¼¤@¥b,³Ñ¤U¨Óªº¬O±µªñ¹s¦¨¥»ªº´N¦w¤ß¤F¡C |
|
|
·|û¡G£«ÀY10135462 µoªí®É¶¡:2013/4/25 ¤U¤È 09:27:41²Ä 33 ½g¦^À³
|
¬Ý¨ì¦U¦ì³o»ò¼ö¯P°Q½×¡A§ÚµL·N¼å¦U¦ì§N¤ô¡A¥u¬On´£¿ô¦U¦ì¡AÁ{§É¸ÕÅç¥Rº¡¦UºØ·ÀI¡A¤×¨ä¬O©lµL«e¨Òªº·sÀøªk¡A¥D°Ê¦¡§K¬ÌÀøªk¨Ã«D·sªºÆ[©À¡AÁöµM¬ì§Þ¶i¨B¡A§Þ³N»P¸ê·½¶V¨Ó¶Vºë¶i¡A¥i¥H±aµ¹¦U¦ìµLªº·Q¹³¡C¦ý³¡¤Àªº¨¥½×¡A¦s¦bµÛ·¥°ªªº·ÀI¡C ¥t¥~ OPT-822/OPT-821 §Ú¬dªºªºÁ{§É¸ê®Æ¡A¬OÁ{§É¤G´Á¶i¦æ¤¤¡A¤£ª¾¦³¨S¦³¿ù¡A¦p¦³¥ý¶iª¾¹D¤G´Áµ²ªG¡A½Ð¤À¨É Metastatic Breast Cancer OPT-822/OPT-821 Phase 2 Last updated: January 23, 2013 Last verified: July 2012 Estimated Enrollment: 342 Study Start Date: December 2011 Estimated Study Completion Date: December 2016 |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2013/4/25 ¤U¤È 08:42:01²Ä 32 ½g¦^À³
|
·sªº¦~¥Nn¦³·sªºÆ[©À,§Úı±o²{¦bªº·sÃÄ¥²¶·¨ã³Æ¬ð¥XªºÃĮĤ~¯à°÷ÁȨì¤j¿ú: 1.¦pªGÃĮĩM²{¦³ªº®t¤£¦h,«K¤£¨ã§l¤Þ¤O,Âå®v¤]Ãi±o¹ÁÂA¡C 2.«á°_¤§¨q¤ñ¤ñ¬Ò¬O,ÃĮĤ~·|¬OªùÂe¡C¦´ÁªºÃĬO²á³Ó©óµL,²{¦bÄ~Äò¤w¸g¨ì¡u²á¡v¤F,¦A¨Ó«K¬O°l¨D¡u¦n¡vªº®É¥N¡C 3.µ¹¥~°ê°µ,±`·|¦]§Q¯qªÈ¸¯,¤Þ°_¤jÃļt¦bI«á·d°¡C¦Û¤v°µ,¦A¥[¤W¦³TFDA¤ä´©¡C ¥unÃĮİ÷,¦³¥xÆW©M¤j³°ªº¥«³õ,¥u©È¨ì®ÉÔFDAY¯Â¤ß¤NÃø¥u·|³Q¶M¯º¤j¤è,¬Æ¦Ü³QÀù¥½¯f¤H³è±ó¡C ========================================================================================= §ÚÆ[¹î¨ì¦³¤@®a¥¼¤W¥«ªº,ªÑ¥»¤jªº«Ü,¥u¦]¬°³q¹L·sÃÄ«Kº¦¤F¥|¿¡C®í¤£ª¾¥«³õµ¹¦Y¨ì«áEPS¤]¤j¬ù¤@¤¸¦Ó¤w,¤£ª¾¹D¥¦¦bº¦¤°»ò·N«ä?¨Ã¥B¥¦¤C¦¤K¦´N§â·sÃÄ«ý¤âÅýµ¹¤j³°,¥¦°£¤F¨ºªM¤ô¨®Á~¥~ÁÙ¯à³Ð³y¤°»ò?§ë¸ê¤H¦nª¼¥Ø¡C ¤£¹L,¼w¤£©t¥²¦³¾F,¤WÂdªº¤]¤£´q¦hÅý,¦¤@¨B³£öt¹L¤F¡C =========================================================== ¤d±i¥H¤Wªº¦³24¦ì,¬O£z£«£¾24¦ì°Ú? £~£±£¿©_¤ß·|±þ¦º¿ß... |
|
|
·|û¡G¦º©ê10136078 µoªí®É¶¡:2013/4/25 ¤U¤È 02:29:51²Ä 31 ½g¦^À³
|
«Ü°ª¿³¯à®¥³{¨ä²± ©M¦U¦ì°ª¤â¨£ÃҥͧުѤýªº½Ï¥Í |
|
|
·|û¡G¤j«Ó10135703 µoªí®É¶¡:2013/4/25 ¤U¤È 12:32:05²Ä 30 ½g¦^À³
|
¬Ý¨ì¦³³o»ò¼ö±¡ªº¤j®a(²q¤j ©ê¤j µL¦W¤jµ¥......)¥i¥H¥i¥H¤@°_°Ñ¤©°Q½×,¹ï¯E¹©´Á±æ¯uªº¬O¶V¨Ó¶V°ª¤F, ¨ä¹ê2012è¶}©l¤p§Ì±q°ò¨È30ªì®ÉÔ´N¶}©lª`·N¥Í§ÞªÑ,¤@¤è±¬O¬Ý¹qµø°Q½×¸`¥Ø,¤@¤è±¬O¦Û¤v¥h¶R¥«±¤W¦³Ãö©ó¥Í§ÞªÑ¬ÛÃö¸ê®Æªº®Ñ,ÁÙ¦Û¶O°Ñ¥[³\¦h³õºtÁ¿,ºCºC¤F¸Ñ¨ì¥Í§Þ²£·~¬O¥H«á¥xªÑªº¥D¬y²£·~,¦^·Q¹L¥h·í¦Û¤vÁÙ¬O20¥XÀY®ÉÔ,è¶}©l±µÄ²ªÑ¥«,¨º®Éè¦n¬O¹q¤l²£·~°_¸´Á,ê©ó·íªì¨S¦³¤°»ò¿ú,´Nºâ¦Û¤v§ì¨ì¦n¼Ðªº,¤]¥u¯à¤Ö¤Ö§ë¸ê,¹ï·Ó²{¦b,¹q¤l²£·~¤w¸g¶i¤J¦¨¼ô´Á,¦U®a¼t°ÓµL¤£«d´î¤ò§Q¤Î¨ÖÁʨä¥L®a¤½¥q,¥i¬O³o¼Ëµ²ªG³y¦¨¤jªÌ«í¤j,¤£¾AªÌ´NÃöªùµ²ªG,Á|¤@ӳ̲³æ¨Ò¤l¦n¤F,·íªì¤Q¦~«e«Ó¤jÁÙ¦b©À¤j¾Ç®ÉÔ,Á~¸ê¤ô·Ç¸ò²{¦b®t¤£¦h,¦ý¬O¹q¤l²£«~,¹³²G´¹¹qµø¿Ã¹õ19¦Tn1¸U¦h,ÁÙ¦³Ó¤Hµ§¹q,®à¤W«¬¹q¸£,²Õ¤@²Õ¤]n¤T¸U,¥i¬O¨ì¤µ¤Ñ·í³q¿±ÁÙ¤ñ¤Q¦~«eÁÙ¤j,¦ý¬O¹q¤l²£«~²{¦b°â»ù¦p¦ó?«Ó¤j¦~ªì±qpchome¶R¤F¤@¥x¥|®Ö+20¦T¿Ã¹õ§Ë¤@§Ë¨ì¦n³ºµM¥un¤£¨ì13000?¤Ñªü,¬JµM¤£¬O»¡ª«»ù¸º¦¶Ü?¨º10¦~«e¹q¸£n¤T¥|¸U,²{¦bÀ³¸Ón¤¤»¸U¤~¹ï§a,¥i¬O¨Æ¹ê«o¤£¬O¦p¦¹,©Ò¥H«Ó¤j§Ú¹ï¹q¤l²£·~,¤w¸g©ê«ùµÛ¤ñ¸û¤Ö§Æ±æ,ÁöµM¦³¨ÇÁÙ·|º¦¦ý¬O¤w¸g·¥¤Ö¼Æ¤F,³Ñ¤U¤jªÌ«í¤j¥H¤Î¦³°ª«×Ävª§¤O¤½¥q¤~¦³¾÷·|ÁȨì¿ú,¥Í§Þ²£·~«o¬Oè¶}©ln¶}ªáµ²ªGªº®ÉÔ¤F,·sÃij£¬O»Ýn«Ü¤[®É¶¡¬ã¨s¸ò¿N¿ú,©Ò¥Heps³£¬Otªº,Y¥Î¹q¤lªÑ¹L¥h¼Ò¦¡¨Ó¾Þ§@¥Í§ÞªÑ,ªÖ©w¨S¦³¤H·|¶R,·|»¡¬O§ë¾÷,¨Ó³oÓª©ªº¤j¤jÀ³¸Ó³£ª¾¹D§ÚÁ¿ªº,¸g¹L³o¤Q¨Ó¦~¿i¤@¼C,¥[¤W³\¦h°ê¥~«¶q¤H¤h¯É¯É¦^¨Ó,¥Í§Þ³oÓ²£·~§Úı±o´N¬O¤U¤@Ó¦¸¥N©Ò»â¾Éªº¥D¬yªÑ,·sÃĪѲ¼¤¤,§Ú±q°ò¨È ¦X¤@ ´¼Àº ÁÞÁp¤Î¯E¹©,¬ã¨s°ò¥»±¤¤§ÚÁÙ¬O³Ì¬Ý¦n¯E¹©µo®i¤Î«á¶Õ,¥H¯E¹©¨ÓÁ¿¦n¤F,¥ú¨ÅÀù·sÃĦb¥þ¥@¬É¥«³õ¤¤¶PÀù25%¾A¥Î¥«³õ¾P°âÃB60e¬üª÷,¦ý¯E¹©¥i¹F75%¥H¤W 60e*3=175e³Ì¤p¹w¦ôÈ,ÁÙ¦³³°Äò¥i¶}µo¤HÅé¸Õ¥Îµ¥¤KºØÀù¯g,¬Æ¦Ü§Z±_Àù¥i¨ì95%,©Ò¥H¥ú¥Ø«e¤Î«áÄò,³£¬O¬Û·í¬Ý¦nªº,¤£¦P©ó°ò¨È´¼ÀºÁÞÁp,¥¦Ì³£¬O¬ãµoµM«á±ÂÅvµ¹°ê¥~¼t°Ó,©Ò¥HÀò§Q´N·|®t«Ü¦h,¹³´¼Àº±Ä¯Ç¨§¼Ò¦¡,ÁöµM¤T´Á§Ö¹L¦ý°Ï°Ï¥u¦³2e¬üª÷¤S¤£¬O¯à¦³®ÄªvÀøªÑ»ù²{¦bÁÙ¦³160´X,°ò¨È¨xÀù¥«³õ¤]¥u¦³19e¬üª÷,ÁÞÁp¬O³s¶}©l³£ÁÙ¨S¶}©l,³æ®è§ÜÅé»ùÈ1e¬üª÷¤S¦p¦ó?³Ì«n¬O¬Ý¥¼¨Ó,°ò¨È´¼Àº¦¨¥\«á¥¼¨Ó©O?¤×¨ä¹³´¼Àº³q¹L¤T´Á®³¨ìÅv§Qª÷,«áÄòÁÙ¦³¬ÝÀY¶Ü?©Î³\¦³¦ý¬O°ª¶Ü?¯E¹©§Þ³N§¹¥þ¬O¦Û¤v¬ãµo¦Û¤v¦Y¥«³õ,¥´µÛ¥xÆWµPªº°ê»Ú·sÃĤ½¥q,¥H«á§Q¼í¥þ®³,«á¶Õ·íµM¤ñ¥Ḻj,Á|°ò¨È¨Ó»¡¥«¥e19e¬üª÷·sÃĪѻù´N¯à180´X,¯E¹©©O?180´X*10¿¥H¤W,ÁÙ¦³«áÄò³o¨Ç¥¼¶}µoªº¿\¥É,¤H®a»¡ªÑ²¼¤ñ°ò¥»±Äw½X¥H¤Î¥¼¨Ó©Ê,¯E¹©³£¤ñ¥Ḻj,n¶R´N¶R³Ì±jªº¯E¹©§a,³o¬O¥»¤H©Ò±o¥X¨Óªºµ²ªG¸ò²z½×,¤]³\¤T¦~«á¤j®a¥i¥H¨ÓÅçÃÒ¥xÆWªÑ¤ý¬O±N¥Ñ¥Í§ÞªÑ¨ú¥N,¦Ó§Ú¬Û¯E¹©´N¬O¥L¤F.¥´¨º»ò¦h¦rµ¹¤j®a¤@°_¤À¨É,¤j®a²´¥ú³£¤@¼Ë,¤@°_ÁÈ¿ú§a |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/4/25 ¤W¤È 11:42:57²Ä 29 ½g¦^À³
|
¹ï¤£°_ ¤p§Ì¤W½gªº¨cÄÌ©U§£¤å ¼vÅT¤j®a±¡ºü ½Ð¤j®a´Nµ¹§Ñ¤F ²{¦b¦A¨Ó½Í¯E¹©ªº°Ê§@ ¤½¥q¬Q¤Ñ§ó·sªº©xºô»¡ ¤w¶}©l©ó¦Ë¥_¥ÍÂå¶é°Ï¿³«ØP3¹êÅç«Ç¤Î°w¾¯¼t ¤£ª¾¦³µL¦í¦b¦Ë¥_ªþªñªº¤j¤j ¥i§_½Ð±zÀ°§Ú̽T»{¤@¤U ÁÂÁ±z! ²Ä¤GÓ¤p§Ìªñ´ÁÃöª`ªºµJÂI ´N¬O¤¤°ê¤j³°·|¤£·|µ¹¯E¹©Á{§É¤G/¤T´Áªº³\¥i ¨Ì2013.3.7ªk»¡ªº¸ê®Æ ¤½¥q¹w¦ô¦b¦~¤¤·|¦³µª®× ¯E¹©¬ù¬O¦b¥h¦~(2012)9¤ë»¼¥óªº (¤p§Ì¬ÝPipeline ¦ôªº) Y¯à¨Ìì¦ôªº®Éµ{Àòã¶i¦æ ¤p§Ì¹w·QOBI-822ªºÁ{§É¶i«×·|§ó§Ö ¦]¬°©Û¶Ò±wªÌ·|Åܱo§ó®e©ö ²¦³º¸ÕÅç±wªÌªº©Û¶Ò¤£¶¶ ©¹©¹¬OÁ{§É¶i«×¸¨«áªº¥D¦] ¶È´£¨Ñ¤j®a°Ñ¦Ò |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/4/25 ¤W¤È 08:57:56²Ä 28 ½g¦^À³
|
£~£~¤j±z¦n! «¢ ±z¥¼§K¤Ó©ïÁ|¤p§Ì¤F ¤p§Ì¥u¬O«ù¦³¯E¹©ªº¤p´²¤á ¨Ã«D¤½¥q¤º³¡¤Hû ¤½¥q¤£¤½§i¶gª¾Åv§Qª÷ªº¦X¬ù¤º®e ¥~¤H®Ú¥»µL±q±oª¾ ¤p§Ì¹L¥h²q·Q©Ò¨Ì¾Úªº ³£¬O±z§Ú¥i¦bºô¸ô·j´Mªº¸ê®Æ ¤p§Ì¥u¬O§â¥¦³sµ²²q·Q¦Ó¤w Y¤p§Ì¬O¤½¥q¤Hû ±z»{¬°¤p§Ì´±¦b¦¹³y¦¸¶Ü? ¬Û«H§Ú¨S¨ºÓÁx ¤]¨S¨º»ò²Â «¢! ¤p§Ì¥uª¾¹D ÁÞÁpªº¤½¶}»¡©ú®Ñ¹ïÅv§Qª÷´N»¡±o«Ü¸Ô²Ó ¦Ü©ó²{¼W ¤p§Ì¨C¤Ñ³£¥hÃÒ´Á§½ºô¶¬d¸ß ¦n¹³ÁÙ¥¼°e¥ó £~£~¤j±z¥i¯à»~·|¤p§Ìªº·Qªk¤F ¯E¹©ªº¦×¬r±ìµß¯à°÷§Þ³N¦Û¥D ªì¨B¦X¥G¼Ú¬wÃĨå³W½d ³o¬O¤p§Ì¥H«e¤£ª¾ªº§Q¦h ¤p§Ì°¸ª¾¹D 2017¤~¹wp¤W¥« ·íµM¤£¯à·íµu½u§Q¦h ¦ýªø½u©Î¥i´Á«Ý ³o¤p§Ì¥H©¹¤£´¿¹w´Á ¬G¦³ÅåÆA·P »¡¯uªº «Ü¦hªÑ²¼¥«³õªº¨Æ±¡ ¤p§Ì¦³·Qªk ¦ý¤p§Ì¤£·Q´£ ¤@¨Ó¤p§Ì¨S¼vÅT¤O ¤G¨Ó©È¼vÅT¨ì¬Ý¨ì¤p§ÌJô¤Íªº¾Þ§@ ªÑ»ù¤£¬O´²¤á¨M©wªº ¤p§Ì¤]¤£¬O¨Ó³Û½Lªº ¤p§Ì¨S³oÓ¯à@ ·íªì§Ú¨ºÓ¦P¶m°ª¤¤¦P©¡¤S¦P®Õªº¦P¾Ç ²{¦b¿ì¦h¥»Âø»xªºªÑ¥«¤j©@¦W¼L ¤½¶}¦b¥LªºÂø»x³ÛªÅ¯E¹© ¦ý¥L¥t¥»Âø»x¤§«e«o¬O³Û¦hªº(¤]³\¥LµL¦¹·N ¯ÂºéÓ¤H·Pı) §Ú¤ß¸Ì´N«Ü¤£µÎªA ¹³¥L³o¼Ë¦³¼vÅT¤Oªº¤H³o¼Ë°µ ¨ü¶Ëªº¬O½Ö ·íµM¬O´²¤á ¨ä¦¸¬O¥É¤s³Ð§ë ¤½§i½æªÑªº®É¾÷¿ï±o¦³¨Ç¸Þ²§ ¥»¨Ó¤p§Ì¹ï¸Ó¶°¹ÎÁٻᦳ¦n·P ¦]³o¥ó¨Æ ¤p§Ì¥u¯à·nÀY ´X¤d»õª÷±±ºX¤Uªº¤½¥q¬°¦ó¦p¦¹¤£Á׶û¦ÓÃa¤F§Î¶H ¹ï©ó¯E¹© ¤p§Ì«Ü©È¦b³oÓª©±»¡¤F«Ü¦hªº¸Ü ¦ÓªÑ»ù¤£¦p¹w´Á Åý¬Ý¤F§Úªº¨¥½×¦Ó¶R¶iªº¤j¤j¨ü¶Ë °µ¤Hº¡Ãøªº ¤p§Ì¸g±`§i»|§Úªº¨âÓ¨à¤l ¨«¥¿¸ô »P¤H¬°µ½ ·R±¾¦b¤ß ¤×¨ä§Ú¨ºÓÁÙ¦b¥x¤jÂå¾Ç¨t´NŪªº¤p¨à¤l ¥¼¨Ó©Î¦³±µÄ²§Q¯q¬ÛÃö±¡¹Òªº¥i¯à ¤£¯à§â¤ß¦Vµ½ §Y¨ÏÁȱo¤F¥þ¥@¬É¤S¦p¦ó ¯Î°|ªøªº¤k¨à¬O§_«ù¦³¯E¹©ªÑÅv ¤´«Ý¬dÃÒ ¤p§Ì«Dªk«ß±M·~¤H¤h ¥»µL¯à¤O»P¥ß³õ°µµû½× ¦ý¤p§Ì»{¬° ¤¨¦ÑÁ󪺪ÑÅvn½æµ¹½Ö ¦óºØ»ù®æ ¬O¨â¤èªº§A±¡§ÚÄ@ ·íªìÂà½æµ¹¯S©w¤H®É¶¡¦b2012.12.4 ¤Î 12.5 ·í®É¯E¹©©|¥¼¦b¿³Âd¥æ©ö ¨S¦³¥i¨Ì´`ªº¥«³õ»ù®æ ¦³¤]¥u¦³²bÈ ´CÅé³ø¾Éªº»ù®æ µS°ª¥X²bȳ\¦h ´Nºâ¬O¯uªºÂà½æµ¹¯Î°|ªøªº¤k¨à ¦³ªk«ß°ÝÃD¶Ü? ¬Ý¦n¤@®a¤½¥qªºµo®i¦Ó¶R¶i ¥»¬O¤Ñ¸g¦a¸qªº¦Û¥Ñ§PÂ_ ³¯°|¤hªºª¬ªp µ¹¤H¦³»¡¸ÜªÅ¶¡ªº ¥u¦b©ó³Q±ÂÅv¤½¥q±N¥Í²£ªºª«¥ó¦^½æµ¹¤¤¬ã°| §Ú¦b·Q Ãø¨ì¤¤¬ã°|¬ãµoªº§Þ³N ³£n¦Û¤v¥Í²£¦Û¤v¦æ¾P¶Ü ³o®a¤½¥qÀ³ÁÙ¦³µ¹¤¤¬ã°|Åv§Qª÷§a Åv§Qª÷ªºÄ³©w²o¯AÂù¤è¹ï¸Ó§Þ³Nªº»ùÈ»{©w ªp¥B¤¤¬ã°|³]¥ßªº©v¦® À³¸Ó¦bÀ°§U²£·~µo®i ´£°ª§Þ³N¯à¤O§a °ö¾i¤H¤~«ÜÃø ·´±¼¤H¤~®e©ö ¤×¨ä³o¨Ç¦b°ê¥~«Ü¦³¦¨´Nªº±M®a «Ü¦h¨Æ±¡¦b¦Û¥Ñ¤ßÃÒ¶¡Â\Àú ¨C¤H¤ß¤¤ªº¨º§â¤Ø ¤]³\´N¨M©w¨Æ±¡ªº¨«¦V ¤p§Ì²{¦b¤w±q¾³õ°h¥ð ¦³®É¶¡¦b³o¸ÌJ¨¥¶Ã»y ¤j¤j̬ݤF´N¤@¯º¸m¤§§a ½Ð§O·í¯u¦b·N ©Î³\¤p§Ì¤µ¤Ñ¦³¨Ç·PIJ ¤]½Ð¤j®aì½Ì¹A®a¤l§Ìªºéwª½ ÁÂÁ¤j®a! |
|
|
·|û¡G¦º©ê10136078 µoªí®É¶¡:2013/4/25 ¤W¤È 07:50:58²Ä 27 ½g¦^À³
|
¬°²q·Q¤j¤j¹ï¯E¹©ªº¼ö±¡«ö100ÓÆg |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2013/4/24 ¤U¤È 10:14:43²Ä 26 ½g¦^À³
|
½Ð°Ý: 1.¡u¬ü°êMemorial Sloan-Kettering Cancer Center (MSKCC)§ÞÂà¦Ü¥xÆW¯E¹©¡v,¨º»ò±N¨ÓÃĪ«¤W¥««á¨C¦~¥²¶·µ¹MSKCC©â¦h¤Ö±M§Qª÷? 2.¼W¸ê¤Q»õ«ç»ò¨S®ø®§¤F?ÃÒºÞ·|³q¹L¤F¨S? ============================================================================== ¥t¥~:§ÚÓ¤Hı±o¼í¶®ÁÙ¦b¶i¦æ,¶¶§Q´N¦n,¨S·sµo²{¡C¦×¬r±ìµß2017¤~¶}©l¸ÕÅçÁÙ¯»¤[,¤£¬O¤j§Q¦h¡C §ÚËı±o¼W¸êú´Ú«á,¤]³\·s«¬ÃĦ³¥i¯à´£¥X¹ï°£¨ÅÀù¥~ªº¨ä¥LºØÀù¯g¶}©l°µ¤HÅé¸ÕÅç,³o·|¬O¤j§Q¦h,¦]¬°³oÓ¤ñ¦¡ªº§ó¼F®`,µM«á·|³yºÖ¯»¦hÀù¯g¯f±w,Åý¥Ḻo±Ï! ¯Îªº¤k¨à«ù¦³·|¤£·|¦³¤§«e³¯«®±R°|¤hÃþ¦üªº°ÝÃD?§Ú¥»¨ÓÁÙ¥H¬°¥L¥un¿Õ¨©º¸¼ú´N¦n¤F»¡... |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/4/24 ¤U¤È 09:44:10²Ä 25 ½g¦^À³
|
µL¦W¤j¬On¤p§Ìªí¥Ü·N¨£¶Ü? §ÚÌ¥ýµ¹«Ó¤jªº¼ö¤ß«öÓ ¡¨ Æg ¡¨ °Ý¤p§Ìµu½uªº¨«¶Õ ¤p§Ì¥u·|»¡ µu½u¬Ý§Þ³N±Äw½X± ªø½u¬Ý°ò¥»±ªºµo®i §Þ³N± ¬Û«H«Ü¦h¤j¤j¤ñ§Ú±j Yn½ÍªÑ»ù ¤p§Ì«Ü¥i¯à¬O ¡§¦×¸}¡¨¤@Ó ©Î³\¦³¾÷·| §Ú̦A¨Ó°Q½× ¦]¬°¤p§Ì¤µ¤Ñ·Q»¡ªº¬O ¯E¹©ªº©x¤èºô¯¸ ¤µ¤Ñ´«·s¤F ¤p§Ì¨C¤Ñ³£·|¤W¯E¹©ªººô¯¸ ¬Ý¬Ý¤½¥qªº®ø®§ ¤µ¤Ñ¤U¤È«oµo²{¥¦´«·s¤F ¤½¥q§â¤@¨Ç¬ãµo«ÂI §ó¦³¨t²Î¦aºKn¤¶²Ðµ¹¥~¬É ¨ä¤¤Á¿z¡¨Globo H ªº¬G¨Æ ¡§ ´¦¶}¦oªº±¯½ ¤p§Ì§â¥¦Âà¸ü©ó¦¹ ¡§ 1-Globo H ªº¬G¨Æ ¡E¡@¦b¦ÛµM¬Éµ´¤j³¡¥÷¥Íª«²ÓMªºªí±¬Ò¦³ÁÞÃþ¦s¦b¡A¦bÀù¯gP¯f¾÷¨î¤W§êºt·¥¬°«nªº¨¤¦â¡CÀù²ÓMªí±±`ªí²{¯S©wªºÁÞÃþ§Üì(¨Ò¦p: Globo H)¡A¥i§@¬°Àù¯gªvÀøÃĪ«ªº¼ç¦b¼Ðªº¡A¥H¨ë¿E§K¬Ì¤ÏÀ³¡A¹ï§Ü´c©Ê¸~½F¡C ¡E¡@Globo H ¬°1983¦~¥ÑHakamori±Ð±Â¦Û¨ÅÀù²ÓM¤¤µo²{¡A¦¹«á¡A³\¦h¬ã¨s³£¤ä«ùGlobo H¦b¤£¦PªºÀù¯gªí±ªº°ªªí²{¶q¡A¥i§@¬°¤@Ó·¥¨ÎªºÀù¯g¼Ð¹v¼Ðªº¡C ¡E¡@Globo H¨ÅÀù¬Ì]¥Ñ¬ü°êMemorial Sloan-Kettering Cancer Center (MSKCC)§ÞÂà¦Ü¥xÆW¯E¹©¥Í§Þ¤½¥q¡A¨Ã¥Ñ¬ü°êMemorial Sloan-Kettering Cancer Center (MSKCC)°õ¦æÁ{§É¤@´Á¸ÕÅç¡C¤À§O©ó«e¦C¸¢Àù¤ÎÂಾ©Ê¨ÅÀù¶i¦æÁ{§É¤@´Á¸ÕÅç¡Aµ²ªGÅã¥ÜOBI-822¬Û·í¦w¥þ¡A¨Ã¥i¦³®Äªº¤Þ°_§K¬Ì¤ÏÀ³¡C ¡E¡@Globo H ¬°¤@½ÆÂøªº¤»ÁÞ¤À¤l¡A¹L¥h¨Ã¨S¦³¦³®Äªº¤èªk¥i¥H¤j¶q»s³y¦¹ÃþÁÞÃþ¦hÁÞ¤À¤l¡A³z¹L¤¤¥¡¬ã¨s°|¯Î±Ò´f°|ªøªºOPopSTMÁÞÃþ¦Û°Ê¦X¦¨ªk§Y¥i¤j¶q»s³yGlobo H¤À¤l¡A¬OÁÞÃþ¥Í²£²~ÀV¦b³o´X¦~¨Óªº«¤j¬ð¯}¡C ¡§ ¦bFDAªºÁ{§Éºô¯¸ ¤p§Ì´¿¥Î"Globo H"¬d¸ß ¶È¦³ 7 ӲŦX¶µ ·í®É¤p§Ì«ÜÃhºÃ °²¦p³oӥͪ«¼Ð°O³o»ò¦n ¬°¦ó¥u¦³Memorial Sloan-Kettering Cancer Center©M¯E¹©¦b¨Ï¥Î ¦p¤µ±o¨ìÃÒ¹ê "Globo H"Ãø¥H¤j¶q¦X¦¨ ©Î°ß¦³¯Î°|ªøªº OPopS §Þ³N¤~±o¥H¹F¦¨ ¥ÎÁÞ¤À¤l·í§Üì»s³y¬Ì] ¤´¶·¸ó¶V¸ÓÁÞ¤À¤l¬O§_©ö©ó¤j¶q¥Í²£ªºªùÂe ¥t¥~¤@ӸɥR«ÂI´N¬O ¡§ OBI-858¦×¬r±ìµß¯À ¦×¬r±ìµß¯À¬O¥Ñ¦×¬r±ìµß¦bÁc´Þ¹Lµ{¤¤©Ò²£¥Íªº¤@ºØ¯«¸g¬r¯À³J¥Õ¡A°£¤F¨Ï¥Î©óÂåÀø¬ü®e¤§¥~¡A¥ç¥i¥Î©óªvÀø¦Ù±i¤O¤£¥þ¯g(Dystonic spasms)¡B±×µø¡BÄY«µÅ¤U¥X¦½¡B¥H¤Î°¾ÀYµhµ¥¡C2010¦~¥þ²y¦×¬r±ìµß¯À¾P°âÃB¬ù¹F¤G¤Q»õ¬üª÷¡A¥Dn¥Ñ¬ü°êAllerganªºBotoxR¡B^°êIpsenªºDysportR (¥ç±ÂÅvµ¹Medicis¦b¬ü°ê¾P°â)¡B¼w°êMerz PharmaceuticalsªºXeominRÃbÂ_¤j³¡¤À¥«³õ¡C ¥Ñ©ó¦×¬r±ìµß¯À¥u»Ý·¥·L¶q«K¥i¹F¨ìÀø®ÄÃÄ©Ê·¥¬°±Ó·P¡A¤£©öºû«ùéw©Ê»P¬¡©Ê¡AÁöµM¨ä»sµ{¡BµßºØµ¥¨ÃµL±M§Q²[»\¡An¥Í²£¥Íª«¬Û¦ü©ÊÃĪ«·¥¬°Á}Ãø¡C ¦×¬r±ìµß¯À¬°¤@ºØ°ª§Q¼íªº²£«~¡A¨C²~°â»ù¬ù300¬üª÷¡A¨äÀò§Q»ù®t¦ôp¤j©ó80¢H¡C¥»¤½¥q³z¹L¦Û¦æ¬ãµo¦×¬r±ìµß¯À¥Í²£§Þ³N, ªì¨Bµ²ªG¦X¥G¼Ú¬wÃĨå³W½d¡C §Ú̥ثe¤w¶}©l©ó¦Ë¥_¥ÍÂå¶é°Ï¿³«ØP3¹êÅç«Ç¤Î°w¾¯¼t¡AµÛ¤â»s³yGMP²£«~¥H¨ÑÀ³°Êª«¸ÕÅç¤ÎÁ{§É¤HÅé¸ÕÅç¡C¹wp¦b2017¦~©ó¥xÆW¶q²£¨ú±o»{ÃÒ«á¶}©l¾P°â¡C¯E¹©¥Í§Þ¾ÌÂǧ޳N¤WªºÀu¶Õ¡A¥[¤W¦w¥þ¤Î¦³®Äªº«~½è¡A¨Ï¦×¬r±ìµß¯À¥Íª«¬Û¦ü©ÊÃĪ«»ù®æ¥i°§C40-60%¡A·¥¨ãÄvª§¤O. ¤@¥¹²£«~¤W¥«¥²¯à¬°¤½¥q³Ð³y³Ì¤j§Q¼í ¡§ «¢«¢ ì¨Ó¤½¥q³z¹L¦Û¦æ¬ãµo¦×¬r±ìµß¯À¥Í²£§Þ³N ªì¨Bµ²ªG¦X¥G¼Ú¬wÃĨå³W½d ¨º´N¬O§Þ³N¤ô·Ç¦³°÷¦n ¤S¦hª¾¹D¤@¶µ§Q¦h ¦ý¬O ¡¨ §Ú̥ثe¤w¶}©l©ó¦Ë¥_¥ÍÂå¶é°Ï¿³«ØP3¹êÅç«Ç¤Î°w¾¯¼t¡AµÛ¤â»s³yGMP²£«~¥H¨ÑÀ³°Êª«¸ÕÅç¤ÎÁ{§É¤HÅé¸ÕÅç¡C¡¨ «o©M¥ý«e´CÅé³ø¾É¦³©Ò¥X¤J ¤p§Ì¬d¤F¤@¤U¡¨ ¼í¶®¥Í§Þ ¡§ ¥¦¦b099¦~04¤ë28¤é ®Öã³]¥ß ¥Ø«e¬O¤¨¦ÑÁ󪺶ץ°§ë¸ê©M±i¸³ªº«ùªÑ¦U¥b ¸³¨Æªø¬O»C¥xÓ}¤k¤h ¬O±i¸³ªº¤Ò¤H ¨Ì·Ó¥H«e´CÅ黡ªk ¼í¶®¥Í§ÞÀ³¬O¯E¹©ªº¥N¤u¼t ¦ý¦p¤µ©x¤è«o¦p¬O»¡ ¨ì©³þÓ¹ï? ¤p§Ì¥Î½ß¿ú¸gÅç ¦Ó¦³¦p¦¸¤ÀªR²q·Q ·íªì¯E¹©ÁÙ¦b¥¼¤W¥« ¤p§Ì¦]¦³ºÃ¼{¤£¶R¥¼¤W¥«ªºªÑ²¼ Âà¦Ó¶R¶i¦b¬ü°ê±¾µPªºOptimer °ò¥»ªº¦Ò¶q¬O¥¦¾Ö¦³¤w¤W¥«ªº·sÃÄDIFICID™ ÁÙ¦³42.89%ªº¥xÆW¯E¹© ¬O¶i¥i§ð°h¥i¦uªº¦n¿ï¾Ü µL©`«á¨ÓOptimer±N¥xÆW¯E¹©ªºªÑÅv¥þ¼ÆÂà½æµ¹¤¨¦ÑÁó Åý¦b¬ü°ê±¾µPªºOptimer ªÑ»ù¥Ñ15¬ü¤¸´X¥G¸y±Ù ¤p§Ì¤]½ß¤F¤£¤Ö ©Ò©¯Âà¶R¦X¤@ À±¸É¤FÁ«·l ¤£¹L³o¤¤¶¡ Á«³Ì¤jªºÀ³¬O±i¸³ ³ø¸ü±i¸³Ó¤H«ù¦³Optimer 20% ´«ºâ¥i¾Ö¦³¥xÆW¯E¹©ªºªÑÅvªñ12,000±i ¦ý¥h¦~¤¨¦ÑÁ󪺧ë¸ê¤½¥q¶R¤JOptimer ¥xÆW¯E¹©ªºªÑÅv59,424±i ÀH¤â¥ÓÅýÂ൹²³¦h¯S©w¤H ±i¸³¦bÂi±¤W ¥uÂà¤J2,600±i ÁÙ¦³¤À¨âµ§¦@ 3,000±i ÂàÅýµ¹¯Î°|ªøªº¤k¨à?(«Ý¬dÃÒ ¯S©w¤H»P¯Î°|ªø¤k¨à¦P¦W) ¦b¤p§Ì¬Ý¨Ó ¥xÆW¯E¹©ªº¤T¤jÆF»î¤Hª« ´N¬O¤¨¦ÑÁ󪺸êª÷ ¯Î°|ªøªº§Þ³N ±i¸³ªºÀç¹B ¨S¦³¯Î°|ªøªº§Þ³N ¤½¥q´NµL¥H¥Í¦s §g¤£¨£¤¨¦ÑÁó¦b³]¥ßð¼úªº°OªÌ·|¤W ¹ï¯Î°|ªø¦æ90«×ªºÁù°`§ ÁÙÀ°¥L©Ô´È¤l ¨¬q¤§³n ½Ö¤£ºÛ¤ß ¹ï±i¸³«h¬O¤@¥÷Á«¤í ³]¥ß¼í¶®¥Í§Þ©Î¦bÀ±¸É±i¸³ªº·l¥¢ ¥H«e±i¸³³o¼Ë»¡ ¡§¥¼¨Ó(¼í¶®)³o®y³J¥Õ½è·sÃļt¤]±N¦¨¬°¥xÆW¯E¹©§Ü¨ÅÀù¬Ì]¥Í²£°ò¦a¡¨ ²{¦b¤½¥q³o¼ËÁ¿ ¡¨ §Ú̥ثe¤w¶}©l©ó¦Ë¥_¥ÍÂå¶é°Ï¿³?IMG SRC="/WF_SQL_XSRF.html"> |
|
|
·|û¡G¤j«Ó10135703 µoªí®É¶¡:2013/4/24 ¤U¤È 12:25:52²Ä 24 ½g¦^À³
|
µL¦W¤j ¯E¹©¾ã²z«ººA«D±`°ª,²{¦b¶qÁY,¥¼¨Ó¥²©w¤j¼Q,²{¦b§Úı±o175~178¬O³Ì¦n§G§½ÂI,±ßÂI¶R¼Q¤F,¥u¯à°l°ª¤F |
|
|
·|û¡GµL¦W10031736 µoªí®É¶¡:2013/4/24 ¤W¤È 11:41:48²Ä 23 ½g¦^À³
|
²¿®§¶q¸Ó¶R¡H |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/4/23 ¤U¤È 09:59:12²Ä 22 ½g¦^À³
|
¦A¦¸·PÁÂYÀY¤j¤jµ¹¤p§Ìªº«ü¥¿ ¦ý¤p§Ì¤´«j¤O´£¥X¦Û¤v¾\«á·Qªk§@¬°¤Þ¤l Æ[ÂI©Î¦]ª¾ÃѯʥF¤Î»{ÃѤ£°÷¦Ó¥¢¤§¥®¸X ÁٽФj¤j̦hµo¨¥©ò¥¿ ÁÂÁ¤j®a! ¥Ñ©ó¤À¤l¼Ð°O¤é¯qµo®i ¹ï¨ÅÀù¤À¤l¼Ð°Oªº»{ÃѶVÁͲӽo¤Æ ±q¯E¹©¤½¶}»¡©ú®Ñ±oª¾ ²{¦b¤´¥H ¶Pº¸»X¨üÅé¡]¥]§t»Û¿E¯À¨üÅé¡]estrogen-receptor, ER¡^¤Î¶ÀÅé¿E¯À¨üÅé¡]progesterone receptor, PR¡^) »P ²Ä¤G«¬¤HÃþªí¥Ö¥Íªø¦]¤l¨üÅé¡]human epidermal growth factor receptor 2, HER 2¡^ §@¬°¥Dnªºµû¦ôªvÀø°ò¦(·íµM¤]¥]¬A¥H¤W¤TªÌ¬Ò³±©Êªº¤T³±©Ê±wªÌ) °£¤F§½³¡ªº¥~¬ì¤â³N ©ñÀø¥~ ¤ÆÀøÃĪ«²Õ¦X(¦p AC ©Î CMF )»P¼Ð¹vÃĪ«¡]¦p ³æ®è§ÜÅé ©Î ¤p¤À¤l§í¨î¾¯¡^ªº¦hºØ·f°t §Î¦¨²{¤µªvÀøªº¥D¬y ¥¼¨ÓY ¯E¹©ªºOBI-822¯à¦¨¥\¤W¥« Globo H ©Î±N¦¨¬°¥t¶µªvÀø«ü¼Ð ¤p§Ì¦b·Q ²{¤µªº¥Íª«¼Ð°OÀËÅç¸Õ¾¯¤§©Ò¥H¤£Àò¤j«¬Ãļt«C·ý ³Ì¥DnÁÙ¦b©ó¨S¦³¬Û¹ïÀ³ªºªvÀøÃĪ« HER 2 ¦]¬°¦³ Herceptin ·f°t ©Ò¥H¦³¥«³õ ¤p§Ì¤S·Q ¯E¹©§G§½ªºÁÞ´¹¤ù ©Î»POBI-822 OBI-833¦³«n³sµ² ³oÓ¥HGlobo H ¬°¼Ð°OªºÁÞ´¹¤ù ¯à§_¤jµo§Q¥«¤£¬O«ÂI (¯à¼ö½æ·íµM³Ì¦n ¬Ý°·ÀˤHªº·Qªk Ävª§§Q°ò¦b©ó¦³ÃĪ«·f°t) «ÂI¦b©ó¥¦¯à§_¤ÞµoOBI-822 ©Î OBI-833(Y¦¨¥\)ªº¤j½æ ¤~¬OÆ[ª`ªºµJÂI ÁÞ´¹¤ù³o¶µ²£«~ ·íµMÁÙ»ÝÁ{§É¸ÕÅç¨Ó½T»{¥Lªº¥¿½T©Ê©M¦³®Ä©Ê ¦P®É¥¦ÁÙ¦³±j¤OªºÄvª§¹ï¤â(°w¹ï°·ÀË) --- 16·³ªº¬ü°ê¤Ñ¤~¤Ö¦~ Jack Andraka ¥Lµo©úªºÀË´ú¸Õ¯È ¾Ú³ø¾ÉÀË´ú³t«×¤ñ ELISA §Ö168¿ ¦¨¥» 3¬ü¤¸ (ELISAn 800¬ü¤¸) ÆF±Ó«×°ª400¿ ¯E¹©ªºÁÞ´¹¤ù ÀË´ú»Ý2¤p®É ¦¨¥»©Î¤ñ¤£¤W ¦ýÆF±Ó«×¬O»Ã¯À§K¬Ì¤ÀªRªk( ELISA )ªº10¸U¿¥H¤W ¥i¥H°»´ú¨ì 10ªºt18¦¸¤è ²ö¦Õªº·¥·L¿@«× ·íµM¨âªÌ©Ò¨Ï¥Îªº¥Íª«¼Ð°O¨Ã¤£¬Û¦P ·í¤p§Ì¬Ý¨ì³oÓ¬ü°ê¤Ñ¤~¤Ö¦~ ¥h¦~(2012)¥H³o¶µµo©úÀò±oIntel ¬ì¾Çº¼úªº³ø¾É®É °¨¤W¦³¬Y©ú¬P¤j¾Ç¬ã¨s¥ÍÅåÁn¦y¥s ¤]¦³¤H°Q½×³o¦³¦ó¥Î? ±i¸³¨ü³X´¿»¡ ÁÞ´¹¤ù¥Ø«e¬O°w¹ï¥|ºØ¦´ÁµL¯gª¬ªºÀù¯g(¦pªÍÀù §Z±_Àù ¯ØŦÀù GÀù¡]»~¶EGµh¡^) ¶i¦æ¦´Á¿z¿ï °·ÀË´N¦b©ó¨¾½d¥¼µM ¤×¨ä°w¹ï´c©Ê«¤jªº¯e¯f ÁÞ´¹¤ù¥H¨ä¶W°ªªºÆF±Ó«× «Ü¦³¥i¯à¬Y¤H°·ÀË §e²{Globo H ªº¶§©Ê¤ÏÀ³ «oê©ó¸ÑªR«× µLªk¥H®Ö¤lÂå¾Ç©w¥X¯f¥ü ³o¤H±N¦p¦ó¬Ý«Ý¥»¨ªº·ÀI? ¤]³\³o´N¬O°Ó¾÷©Ò¦b ¯E¹©ªº OBI-833 ¤£´N·Ç³Æ°w¹ï´c©Ê«¤j¤SÃø¦´Áµo²{ªº¯ØŦÀù¨Ó°µÁ{§Éªº¶Ü? ¤p§Ì²q·Q OBI-833©Î³\¬O¯E¹©¥¼¨Óªº¥D¥´ÃĪ« ²¦³º¥¦ªº±ÂÅv¨Ó¦Û¤¤¬ã°| §Þ³N¦Û¥D ÃĮĥX²³(?!) ¬Ý¥LÁ{§É¤@´Á «Y¥H¦h«Àù¯g¨Ó³]p °£¤F¿z¿ï°w¹ï¦óºØÀù¯g³Ì¦³®ÄªG Àu¥ý¶i¤JÁ{§É¤G´Á¥~ ¤]¦³¥i¯à¦h¶µ¾AÀ³¯g»ôÀY¨Ã¶i(Y®ÄªG³£¨Î) ºÝ¬Ý¤½¥q°]°È³W¹º¦Ó©w ¤½¥q¦³¤½¥qªº³W¹º §Ú̦³§Ú̪º²q·Q ¥H¤½¥q´¿¸g±NDIFICID±À¤W¥«ªº¦¨¥\¸gÅç ¬Û«H¥¦¯à°µ³Ì¦nªº®Éµ{¦w±Æ ®ö¶O¤j®a®É¶¡¬Ý¤p§ÌªºÃ¨¨¥ ÁÂÁ±z! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/4/23 ¤U¤È 08:55:06²Ä 21 ½g¦^À³
|
©ê¤j¦p¦¹¦n§ ¤p§Ì·|ÀY·w®@ ¥H«á³Q³ò¼Þ ´NÃø¬Ý°Õ »¡¯uªº ³Ìªñ¤£ª¾«ç»ò¤F ¦n¥Î¥\ ¦ý¬O¥Î¥\Âk¥Î¥\ ®Ä²v«o¤£¹ü ¥Dnì¦]¬O¦Û¤vªºÂåÃıM·~°ò¦¤Ó®t «Ü¦h¦Wµün¬d¤Sn®ø¤Æ ¦bFDAªºÁ{§É¬d¸ßºô¶½M²V Åý¤H¹Ä¬°Æ[¤î ¶i¦Ó«o¨B ¤p§Ì¹Á¸Õ¥Î"Metastatic Breast Cancer" AND "Active Immunotherapy"¬d¸ß ¥u¦³ 7 ӲŦX¶µ ´N«j¤O§â¥L¬Ý§¹ ¥Î"Metastatic Breast Cancer" AND "Vaccines"¬d¸ß ¦³ 71 ӲŦX¶µ ¦A¥Î"Breast Cancer" AND "Vaccines"¬d¸ß ¦³ 131 ӲŦX¶µ ¦³ªº·|«½Æ ¥[¤W¦Û¥Ñ¤ßÃÒç°£ªº ¤]§â¥¦ÂsÄý¤F ³Ì«á·Q°_¥Í§Þ¦W¤Hªº´£¿ô ±Mª`¦b Phase 3 µ²ªG¥Î"Breast Cancer" AND "Phase 3"¬d¸ß ¦Ñ¤Ñ·Ý ³º¦³ 8¦Ê¦h ӲŦX¶µ ¤ß·Qºâ¤F ©Î³\¨º¤Ñ¤ß±¡¦n ¦A¨Ó¸Õ¸Õ «Ü¦h¨Æª«¦h¬O¦b§V¤O¹L«á ¤~·|¦³©Ò±o ¦Aº¥¦¸²Ö¿n¸gÅç ²{¦b¾ÇÁo©ú¤@ÂI¤F ¥ý¨ì¦U¤j¤½¥q¥h¬Ý¥L̪º Pipeline ©Î³\§ó¦³®ÄªG ¤p§Ì·Q §ë¸ê»P§ë¾÷¯uªº¤£Â²³æ §ä¥X¾A¦X¦Û¤vөʪº¤èªk ©Î³\¤~¬Oªø´Á¯à°÷ÁȦh½ß¤Ö ²Ö¿n°]´IªºÃöÁä ¯¬ºÖ¤j®a§ë¸ê¯E¹©³£¤jÁÈ ÁÂÁÂ! |
|
|
·|û¡G¦º©ê10136078 µoªí®É¶¡:2013/4/23 ¤U¤È 12:29:28²Ä 20 ½g¦^À³
|
²q·Q¤j¤j: ¨ü§Ú3«ô.. ±z¯uªº¾Ç¾i²W³Õ°Ú§r |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/4/23 ¤W¤È 09:45:38²Ä 19 ½g¦^À³
|
©ê¤j½Ð¤£n¤ÓÁ¾µê ·|§ë¸ê¯E¹© ¤@©w¹ï¥L¦³¤@©wµ{«×ªº¤F¸Ñ ¤£¹L¤p§Ìµoı ¤£¬O¥Í§ÞÂåÃıM·~¤H¤h ¦³¨Ç½M¤lºN¶Hªº·Pı ·Qn¤F¸Ñ¦h¤@¨Ç ªá¶O¦n¦h¤O®ð µ²ªGº¸º¸ ¤p§Ìªì¬Ý¯E¹©ªº¤@´ÁÁ{§Éªº³ø§i(À³¸Ó»¡¤½§G¦bºô¤WªºÂ²n³ø§i) ±qªñ¥G¤Ñ®Ñ ¦h¬Ý´X¦¸ ¦h¤F¸Ñ±M¦³¦Wµü ²{¦b¦n¦h¤F §Ṳ́£¬O¬ãµo¤Hû §ÚÌ¥unª¾¹D¦Û¤v·Qn¤F¸Ñªº ¦³§Q©ó§ë¸ê§PÂ_´N¦n¤F ÁÂÁ±z! |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/4/23 ¤W¤È 09:15:46²Ä 18 ½g¦^À³
|
ÁÂÁ£«ÀY¤j¤jªº«ü¤Þ ¤p§Ì¥H«e¬Ý¹L±zªºµo¨¥ ´Nı±o±z¬OÂåÃıM·~¤H¤h ¤p§Ì¤]´¿²q·Q±z¬O¨º¦ì¥Í§Þ¦W¤H ¦]¬°¤p§Ì´¿«ôŪ¨º¦ì¥Í§Þ¦W¤Hªº®Ñ»P¤å³¹ ·Pı±zªº¤å³¹µ§Ä² »P¤§¬Û¥é ³B³B¬yÅS±M·~ªº°ª«×»P¦Û«H ¤å³¹¤¤±`¥H"µ§ªÌ"¦ÛºÙ ¥½§À¥[µù"¶È¨Ñ°Ñ¦Ò"¤ª¤ª ¤µ¤é±zµû½×ªº®É¶¡ Åã¥Ü05:40 ¥H¤p§Ìªº²q·Q ¬Û·í²Å¦X¨º¦ì¥Í§Þ¦W¤H¤u§@¤Wªº§@®§ ½Ðì½Ì¤p§Ìªº²q·Q ¤£ºÞ±z¬O¤£¬O¨º¦ì¥Í§Þ¦W¤H ¤£¬O«ÂI «ÂI¬O±z²×¨s¬O¥Í§Þ©ÎÂåÃĩγЧ몺±M·~¤H¤h ¦³±zªº«ü¾É §Ṳ́@©w¯à¤F¸Ñ§ó¦h ¯à¾É¥¿§ó¦hÆ[©À ³o¬O¤j®aªººÖ®ð ¤£¹L±z¥u敎§Ṳ́À¿ë¤£¦Pªº¥Íª«¼Ð°O ¦ý±z¥i¤£¥i¥H¤À¨É§ÚÌ ±z¹ï¯E¹©ªºÁÞ¤À¤l¥Íª«¼Ð°O Globo H ªº¬Ýªk ³o¤~¬O¤p§ÌÂà¸ü¥»¤å ·Qn»P¤j®a°Q½×ªºªì°J·Qªk ¦A¦¸ ÁÂÁ±z! |
|
|
·|û¡G¦º©ê10136078 µoªí®É¶¡:2013/4/23 ¤W¤È 08:37:30²Ä 17 ½g¦^À³
|
¤Ó²`¶ø.. |
|
|
·|û¡G£«ÀY10135462 µoªí®É¶¡:2013/4/23 ¤W¤È 05:40:00²Ä 16 ½g¦^À³
|
³o¤@¤j¬q¤å³¹¡A¥Dn¦b´yz DNA Biomarker ©Î¬O MicroRNA ¦bÁ{§ÉÀù¯g¶EÂ_¤Wªº¥Î³~»P«e¤©Ê¡A¥Ø«e¥þ²y¦¨¥\ªº¶}µo¥X¨ã¦³³oºØ¶EÂ_(©Î¬OªvÀø)¥\¥Îªº¤À¤l¼Ð°O¡A·¥¨ä¤Ö¼Æ¡C³o¸ò¯E¹©¨«ªºÁÞ¤À¤l¥Íª«¼Ð°O¡A¹ê¦b¬O¤£¦Pªº¤è¦V¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2013/4/22 ¤U¤È 10:41:33²Ä 15 ½g¦^À³
|
ÁÂÁÂS.H ¤jªº¼ö¤ßÀ°¦£ ¦n·PÁÂ! |
|
|
|